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1. Introduction to deep learning
Biology and medicine are rapidly becoming data-intensive.
A recent comparison of genomics with social media, online
videos and other data-intensive disciplines suggests that genomics alone will equal or surpass other fields in data generation
and analysis within the next decade [1]. The volume and complexity of these data present new opportunities, but also pose
new challenges. Automated algorithms that extract meaningful
patterns could lead to actionable knowledge and change how
we develop treatments, categorize patients or study diseases,
all within privacy-critical environments.
The term deep learning has come to refer to a collection of
new techniques that, together, have demonstrated breakthrough gains over existing best-in-class machine learning
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Deep learning describes a class of machine learning
algorithms that are capable of combining raw inputs into
layers of intermediate features. These algorithms have
recently shown impressive results across a variety of domains.
Biology and medicine are data-rich disciplines, but the
data are complex and often ill-understood. Hence, deep learning techniques may be particularly well suited to solve
problems of these fields. We examine applications of deep
learning to a variety of biomedical problems—patient classification, fundamental biological processes and treatment of
patients—and discuss whether deep learning will be able to
transform these tasks or if the biomedical sphere poses
unique challenges. Following from an extensive literature
review, we find that deep learning has yet to revolutionize
biomedicine or definitively resolve any of the most pressing
challenges in the field, but promising advances have been
made on the prior state of the art. Even though improvements
over previous baselines have been modest in general, the
recent progress indicates that deep learning methods will
provide valuable means for speeding up or aiding human
investigation. Though progress has been made linking a
specific neural network’s prediction to input features, understanding how users should interpret these models to make
testable hypotheses about the system under study remains
an open challenge. Furthermore, the limited amount
of labelled data for training presents problems in some
domains, as do legal and privacy constraints on work with
sensitive health records. Nonetheless, we foresee deep learning enabling changes at both bench and bedside with the
potential to transform several areas of biology and medicine.

algorithms across several fields. For example, over the past 5
years, these methods have revolutionized image classification
and speech recognition due to their flexibility and high accuracy
[2]. More recently, deep learning algorithms have shown
promise in fields as diverse as high-energy physics [3], computational chemistry [4], dermatology [5] and translation among
written languages [6]. Across fields, ‘off-the-shelf’ implementations of these algorithms have produced comparable or
higher accuracy than previous best-in-class methods that
required years of extensive customization, and specialized
implementations are now being used at industrial scales.
Deep learning approaches grew from research on artificial
neurons, which were first proposed in 1943 [7] as a model for
how the neurons in a biological brain process information.
The history of artificial neural networks—referred to as
‘neural networks’ throughout this article—is interesting in its
own right [8]. In neural networks, inputs are fed into the
input layer, which feeds into one or more hidden layers,
which eventually link to an output layer. A layer consists of a
set of nodes, sometimes called ‘features’ or ‘units’, which are
connected via edges to the immediately earlier and the
immediately deeper layers. In some special neural network
architectures, nodes can connect to themselves with a delay.
The nodes of the input layer generally consist of the variables
being measured in the dataset of interest—for example, each
node could represent the intensity value of a specific pixel in
an image or the expression level of a gene in a specific transcriptomic experiment. The neural networks used for deep
learning have multiple hidden layers. Each layer essentially
performs feature construction for the layers before it. The training process used often allows layers deeper in the network to
contribute to the refinement of earlier layers. For this reason,
these algorithms can automatically engineer features that are
suitable for many tasks and customize those features for one
or more specific tasks.
Deep learning does many of the same things as more familiar machine learning approaches. In particular, deep learning
approaches can be used both in supervised applications—where
the goal is to accurately predict one or more labels or outcomes
associated with each data point—in the place of regression
approaches, as well as in unsupervised, or ‘exploratory’ applications—where the goal is to summarize, explain or identify
interesting patterns in a dataset—as a form of clustering.
Deep learning methods may, in fact, combine both of these
steps. When sufficient data are available and labelled, these
methods construct features tuned to a specific problem and
combine those features into a predictor. In fact, if the dataset
is ‘labelled’ with binary classes, a simple neural network
with no hidden layers and no cycles between units is equivalent to logistic regression if the output layer is a sigmoid
(logistic) function of the input layer. Similarly, for continuous
outcomes, linear regression can be seen as a single-layer
neural network. Thus, in some ways, supervised deep learning
approaches can be seen as an extension of regression models
that allow for greater flexibility and are especially well suited
for modelling nonlinear relationships among the input features. Recently, hardware improvements and very large
training datasets have allowed these deep learning techniques
to surpass other machine learning algorithms for many problems. In a famous and early example, scientists from Google
demonstrated that a neural network ‘discovered’ that cats,
faces and pedestrians were important components of online
videos [9] without being told to look for them. What if, more
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Figure 1. Neural networks come in many different forms. Left: A key for the various types of nodes used in neural networks. Simple FFNN: a feed-forward neural
network in which inputs are connected via some function to an output node and the model is trained to produce some output for a set of inputs. MLP: the multilayer perceptron is a feed-forward neural network in which there is at least one hidden layer between the input and output nodes. CNN: the convolutional neural
network is a feed-forward neural network in which the inputs are grouped spatially into hidden nodes. In the case of this example, each input node is only
connected to hidden nodes alongside their neighbouring input node. Autoencoder: a type of MLP in which the neural network is trained to produce an
output that matches the input to the network. RNN: a deep recurrent neural network is used to allow the neural network to retain memory over time or sequential
inputs. This figure was inspired by the Neural Network Zoo by Fjodor Van Veen.
generally, deep learning takes advantage of the growth of data
in biomedicine to tackle challenges in this field? Could these
algorithms identify the ‘cats’ hidden in our data—the patterns
unknown to the researcher—and suggest ways to act on them?
In this review, we examine deep learning’s application to biomedical science and discuss the unique challenges that biomedical
data pose for deep learning methods.
Several important advances make the current surge of
work done in this area possible. Easy-to-use software packages
have brought the techniques of the field out of the specialist’s
toolkit to a broad community of computational scientists.
Additionally, new techniques for fast training have enabled
their application to larger datasets [10]. Dropout of nodes,
edges and layers makes networks more robust, even when
the number of parameters is very large. Finally, the larger datasets now available are also sufficient for fitting the many
parameters that exist for deep neural networks. The convergence of these factors currently makes deep learning
extremely adaptable and capable of addressing the nuanced
differences of each domain to which it is applied.
This review discusses recent work in the biomedical domain,
and most successful applications select neural network architectures that are well suited to the problem at hand. We sketch out a
few simple example architectures in figure 1. If data have a natural adjacency structure, a convolutional neural network (CNN)
can take advantage of that structure by emphasizing local
relationships, especially when convolutional layers are used in
early layers of the neural network. Other neural network architectures such as autoencoders require no labels and are now
regularly used for unsupervised tasks. In this review, we do
not exhaustively discuss the different types of deep neural network architectures; an overview of the principal terms used
herein is given in table 1. Table 1 also provides select example
applications, though in practice each neural network architecture has been broadly applied across multiple types of
biomedical data. A recent book from Goodfellow et al. [11]
covers neural network architectures in detail, and LeCun et al.
[2] provide a more general introduction.
While deep learning shows increased flexibility over other
machine learning approaches, as seen in the remainder of this
review, it requires large training sets in order to fit the hidden
layers, as well as accurate labels for the supervised learning
applications. For these reasons, deep learning has recently
become popular in some areas of biology and medicine,
while having lower adoption in other areas. At the same

time, this highlights the potentially even larger role that it
may play in future research, given the increases in data in
all biomedical fields. It is also important to see it as a
branch of machine learning and acknowledge that it has the
same limitations as other approaches in that field. In particular, the results are still dependent on the underlying study
design and the usual caveats of correlation versus causation
still apply—a more precise answer is only better than a less
precise one if it answers the correct question.

1.1. Will deep learning transform the study of
human disease?
With this review, we ask the question: what is needed for deep
learning to transform how we categorize, study and treat
individuals to maintain or restore health? We choose a high
bar for ‘transform’. Grove [12], the former CEO of Intel,
coined the term Strategic Inflection Point to refer to a change
in technologies or environment that requires a business to be
fundamentally reshaped. Here, we seek to identify whether
deep learning is an innovation that can induce a Strategic
Inflection Point in the practice of biology or medicine.
There are already a number of reviews focused on applications of deep learning in biology [13–17], healthcare
[18–20] and drug discovery [4,21–23]. Under our guiding
question, we sought to highlight cases where deep learning
enabled researchers to solve challenges that were previously
considered infeasible or makes difficult, tedious analyses routine. We also identified approaches that researchers are using
to sidestep challenges posed by biomedical data. We find
that domain-specific considerations have greatly influenced
how to best harness the power and flexibility of deep learning.
Model interpretability is often critical. Understanding the
patterns in data may be just as important as fitting the data.
In addition, there are important and pressing questions about
how to build networks that efficiently represent the underlying structure and logic of the data. Domain experts can
play important roles in designing networks to represent data
appropriately, encoding the most salient prior knowledge
and assessing success or failure. There is also great potential
to create deep learning systems that augment biologists and
clinicians by prioritizing experiments or streamlining tasks
that do not require expert judgement. We have divided the
large range of topics into three broad classes: disease and
patient categorization, fundamental biological study and
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edges connecting nodes in different layers or
creating cycles within layers, correspond to
inputs to mathematical functions
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hidden node

3

machine learning approaches with goal of prediction of labels or outcomes
machine learning approaches with goal of data summarization or pattern identiﬁcation

machine learning approach inspired by biological neurons where inputs are fed into one or more
layers, producing an output layer

NN with multiple hidden layers. Training happens over the network, and consequently such
architectures allow for feature construction to occur alongside optimization of the overall training

supervised learning
unsupervised learning

neural network (NN)

deep neural network

type of FFNN with at least one hidden layer where each deeper layer is a nonlinear function of each
earlier layer

an NN with layers in which connectivity preserves local structure. If the data meet the underlying

MLP

CNN

this special type of AE includes a step where noise is added to the input during the training

variational

autoencoder (VAE)
denoising autoencoder

models can be sampled to produce hypothetical examples
a generative NN that forms the building block for many deep learning approaches, having a single

generative neural

network
RBM

input layer and a single hidden layer, with no connections between the nodes within each layer

is inherently noisy
neural networks that fall into this class can be used to generate data similar to input data. These

mRNA expression and miRNA expression)
(Continued.)

here can be used in a generative fashion
RBMs have been applied to combine multiple types of omic data (e.g. DNA methylation,

a number of the unsupervised learning neural network architectures that are summarized

data extracted from the EHR

domain, and some early publications have used VAEs to analyse gene expression data
like AEs, DAs have been used for unsupervised analysis of gene expression data as well as
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process. The denoising step acts as smoothing and may allow for effective use on input data that

data extracted from the EHR
VAEs have been shown to often produce meaningful reduced representations in the imaging

layer. Such neural networks are unsupervised and are often used for dimensionality reduction
this special type of generative AE learns a probabilistic latent variable model
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(DA)

autoencoders have been used for unsupervised analysis of gene expression data as well as

an NN where the training objective is to minimize the error between the output layer and the input

autoencoder (AE)

LSTMs are gaining a substantial foothold in the analysis of natural language, and may
become more widely applied to biological sequence data

this special type of RNN has features that enable models to capture longer-term dependencies

LSTM neural network

the RNN architecture is used for sequential data—such as clinical time series and text or
genome sequences

a neural network with cycles between nodes within a hidden layer.

medical and microscopy images

CNNs are used for sequence data—such as DNA sequences—or grid data—such as

MLPs do not impose structure and are frequently used when there is no natural ordering of
the inputs (e.g. as with gene expression measurements)

most of the examples below are special cases of FFNNs, except recurrent neural networks

example applications

recurrent neural
network (RNN)

assumptions performance is often good, and such networks can require fewer examples to train
effectively because they have fewer parameters and also provide improved efﬁciency

NN that does not have cycles between nodes in the same layer

feed-forward neural
network (FFNN)

objective

deﬁnition

term

Table 1. Glossary.
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transformations for biomedical images often do not change relevant properties of the
image

data augmentation is widely used in the analysis of images because rotation

adversarial training has been used in image analysis

contain individual-level records and are subject to sharing restrictions. They have also
been applied to generate microscopy images

DBNs can be used to predict new relationships in a drug– target interaction network
GANs can synthesize new examples with the same statistical properties of datasets that

example applications

A key challenge in biomedicine is the accurate classification
of diseases and disease subtypes. In oncology, current ‘gold
standard’ approaches include histology, which requires
interpretation by experts, or assessment of molecular markers
such as cell surface receptors or gene expression. One example
is the PAM50 approach to classifying breast cancer where the
expression of 50 marker genes divides breast cancer patients
into four subtypes. Substantial heterogeneity still remains
within these four subtypes [24,25]. Given the increasing
wealth of molecular data available, a more comprehensive
subtyping seems possible. Several studies have used deep
learning methods to better categorize breast cancer patients:
for instance, denoising autoencoders, an unsupervised
approach, can be used to cluster breast cancer patients [26],
and CNNs can help count mitotic divisions, a feature that is
highly correlated with disease outcome in histological images
[27]. Despite these recent advances, a number of challenges
exist in this area of research, most notably the integration of
molecular and imaging data with other disparate types
of data such as electronic health records (EHRs).

input as training examples to make the resulting NN robust (no relation to GANs)
a process by which transformations that do not affect relevant properties of the input data (e.g.
data augmentation

arbitrary rotations of histopathology images) are applied to training examples to increase the size
of the training set

a process by which artiﬁcial training examples are maliciously designed to fool an NN and then

generator, is provided with a set of randomly generated inputs and tasked with generating
samples. The second, the discriminator, is trained to differentiate real and generated samples.
network (GAN)

adversarial training

generative NN with several hidden layers, which can be obtained from combining multiple RBMs
a generative NN approach where two neural networks are trained. One neural network, the
DBN
generative adversarial

After the two neural networks are trained against each other, the resulting generator can be used
to produce new examples

deﬁnition
term

Table 1. (Continued.)

1.1.2. Fundamental biological study
Deep learning can be applied to answer more fundamental
biological questions; it is especially suited to leveraging large
amounts of data from high-throughput ‘omics’ studies. One
classic biological problem where machine learning, and now
deep learning, has been extensively applied is molecular
target prediction. For example, deep recurrent neural networks
(RNNs) have been used to predict gene targets of microRNAs
(miRNAs) [28], and CNNs have been applied to predict protein
residue–residue contacts and secondary structure [29–31].
Other recent exciting applications of deep learning include recognition of functional genomic elements such as enhancers and
promoters [32–34] and prediction of the deleterious effects of
nucleotide polymorphisms [35].

1.1.3. Treatment of patients
Although the application of deep learning to patient treatment
is just beginning, we expect new methods to recommend
patient treatments, predict treatment outcomes and guide the
development of new therapies. One type of effort in this area
aims to identify drug targets and interactions or predict drug
response. Another uses deep learning on protein structures to
predict drug interactions and drug bioactivity [36]. Drug repositioning using deep learning on transcriptomic data is another
exciting area of research [37]. Restricted Boltzmann machines
(RBMs) can be combined into deep belief networks (DBNs)
to predict novel drug–target interactions and formulate drug
repositioning hypotheses [38,39]. Finally, deep learning is
also prioritizing chemicals in the early stages of drug discovery
for new targets [23].

2. Deep learning and patient categorization
In healthcare, individuals are diagnosed with a disease or
condition based on symptoms, the results of certain diagnostic tests, or other factors. Once diagnosed with a disease, an

J. R. Soc. Interface 15: 20170387
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treatment of patients. Below, we briefly introduce the types of
questions, approaches and data that are typical for each class in
the application of deep learning.
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Deep learning methods have transformed the analysis of natural images and video, and similar examples are beginning to
emerge with medical images. Deep learning has been used to
classify lesions and nodules; localize organs, regions, landmarks and lesions; segment organs, organ substructures and
lesions; retrieve images based on content; generate and enhance
images; and combine images with clinical reports [19,40].
Though there are many commonalities with the analysis
of natural images, there are also key differences. In all cases
that we examined, fewer than one million images were available for training, and datasets are often many orders of
magnitude smaller than collections of natural images.
Researchers have developed subtask-specific strategies to
address this challenge.
Data augmentation provides an effective strategy for working with small training sets. The practice is exemplified by a
series of papers that analyse images from mammographies
[41–45]. To expand the number and diversity of images,
researchers constructed adversarial [44] or augmented [45]
examples. Adversarial training examples are constructed by
selecting targeted small transformations to input data that
cause a model to produce very different outputs. Augmented
training applies perturbations to the input data that do not
change the underlying meaning, such as rotations for pathology images. An alternative in the domain is to train towards
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2.1. Imaging applications in healthcare

human-created features before subsequent fine-tuning [42],
which can help to sidestep this challenge though it does give
up deep learning techniques’ strength as feature constructors.
A second strategy repurposes features extracted from natural images by deep learning models, such as ImageNet [46],
for new purposes. Diagnosing diabetic retinopathy through
colour fundus images became an area of focus for deep learning researchers after a large labelled image set was made
publicly available during a 2015 Kaggle competition [47].
Most participants trained neural networks from scratch
[47–49], but Gulshan et al. [50] repurposed a 48-layer Inception-v3 deep architecture pre-trained on natural images and
surpassed the state-of-the-art specificity and sensitivity. Such
features were also repurposed to detect melanoma, the
deadliest form of skin cancer, from dermoscopic [51,52] and
non-dermoscopic images of skin lesions [5,53,54] as well as
age-related macular degeneration [55]. Pre-training on natural
images can enable very deep networks to succeed without
overfitting. For the melanoma task, reported performance
was competitive with or better than a board of certified dermatologists [5,51]. Reusing features from natural images is also an
emerging approach for radiographic images, where datasets
are often too small to train large deep neural networks without
these techniques [56–59]. A deep CNN trained on natural
images boosts performance in radiographic images [58]. However, the target task required either re-training the initial model
from scratch with special preprocessing or fine-tuning of the
whole network on radiographs with heavy data augmentation
to avoid overfitting.
The technique of reusing features from a different task falls
into the broader area of transfer learning (see Discussion).
Though we have mentioned numerous successes for the transfer of natural image features to new tasks, we expect that a
lower proportion of negative results have been published.
The analysis of magnetic resonance images is also faced with
the challenge of small training sets. In this domain, Amit
et al. [60] investigated the trade-off between pre-trained
models from a different domain and a small CNN trained
only with MRI images. In contrast with the other selected literature, they found a smaller network trained with data
augmentation on a few hundred images from a few dozen
patients can outperform a pre-trained out-of-domain classifier.
Another way of dealing with limited training data is to
divide rich data—e.g. 3D images—into numerous reduced projections. Shin et al. [57] compared various deep network
architectures, dataset characteristics and training procedures
for computer tomography (CT)-based abnormality detection.
They concluded that networks as deep as 22 layers could be
useful for 3D data, despite the limited size of training datasets.
However, they noted that choice of architecture, parameter setting and model fine-tuning needed is very problem- and
dataset-specific. Moreover, this type of task often depends on
both lesion localization and appearance, which poses challenges for CNN-based approaches. Straightforward attempts
to capture useful information from full-size images in all
three dimensions simultaneously via standard neural network
architectures were computationally unfeasible. Instead, twodimensional models were used to either process image slices
individually (2D) or aggregate information from a number of
2D projections in the native space (2.5D).
Roth et al. [61] compared 2D, 2.5D and 3D CNNs on a
number of tasks for computer-aided detection from CT
scans and showed that 2.5D CNNs performed comparably

rsif.royalsocietypublishing.org

individual might be assigned a stage based on another set of
human-defined rules. While these rules are refined over time,
the process is evolutionary and ad hoc, potentially impeding
the identification of underlying biological mechanisms and
their corresponding treatment interventions.
Deep learning methods applied to a large corpus of
patient phenotypes may provide a meaningful and more
data-driven approach to patient categorization. For example,
they may identify new shared mechanisms that would otherwise be obscured due to ad hoc historical definitions of
disease. Perhaps deep neural networks, by reevaluating
data without the context of our assumptions, can reveal
novel classes of treatable conditions.
In spite of such optimism, the ability of deep learning
models to indiscriminately extract predictive signals must
also be assessed and operationalized with care. Imagine a
deep neural network is provided with clinical test results
gleaned from EHRs. Because physicians may order certain
tests based on their suspected diagnosis, a deep neural network may learn to ‘diagnose’ patients simply based on the
tests that are ordered. For some objective functions, such as predicting an International Classification of Diseases (ICD) code,
this may offer good performance even though it does not provide insight into the underlying disease beyond physician
activity. This challenge is not unique to deep learning
approaches; however, it is important for practitioners to be
aware of these challenges and the possibility in this domain
of constructing highly predictive classifiers of questionable
utility.
Our goal in this section is to assess the extent to which deep
learning is already contributing to the discovery of novel categories. Where it is not, we focus on barriers to achieving
these goals. We also highlight approaches that researchers are
taking to address challenges within the field, particularly
with regards to data availability and labelling.

2.2. Text applications in healthcare
Owing to the rapid growth of scholarly publications and EHRs,
biomedical text mining has become increasingly important in
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Rich clinical information is stored in EHRs. However,
manually annotating a large set requires experts and is timeconsuming. For chest X-ray studies, a radiologist usually
spends a few minutes per example. Generating the number
of examples needed for deep learning is infeasibly expensive.
Instead, researchers may benefit from using text mining to generate annotations [69], even if those annotations are of modest
accuracy. Wang et al. [70] proposed to build predictive deep
neural network models through the use of images with weak
labels. Such labels are automatically generated and not verified
by humans, so they may be noisy or incomplete. In this case,
they applied a series of natural language processing (NLP)
techniques to the associated chest X-ray radiological reports.
They first extracted all diseases mentioned in the reports
using a state-of-the-art NLP tool, then applied a new method,
NegBio [71], to filter negative and equivocal findings in the
reports. Evaluation of four independent datasets demonstrated
that NegBio is highly accurate for detecting negative and
equivocal findings (approx. 90% in the F1 score, which balances
precision and recall [72]). The resulting dataset [73] consisted of
112 120 frontal-view chest X-ray images from 30 805 patients,
and each image was associated with one or more text-mined
(weakly labelled) pathology categories (e.g. pneumonia and
cardiomegaly) or ‘no finding’ otherwise. Further, Wang et al.
[70] used this dataset with a unified weakly supervised
multi-label image classification framework to detect common
thoracic diseases. It showed superior performance over a
benchmark using fully labelled data.
Another example of semi-automated label generation for
hand radiograph segmentation employed positive mining,
an iterative procedure that combines manual labelling with
automatic processing [74]. First, the initial training set was
created by manually labelling 100 of 12 600 unlabelled radiographs that were used to train a model and predict labels for
the rest of the dataset. Then, poor-quality predictions were
discarded through manual inspection, the initial training set
was expanded with the acceptable segmentations, and the
process was repeated. This procedure had to be repeated
six times to obtain good quality segmentation labelling for
all radiographs, except for 100 corner cases that still required
manual annotation. These annotations allowed accurate segmentation of all hand images in the test set and boosted the
final performance in radiograph classification [74].
With the exception of natural image-like problems (e.g.
melanoma detection), biomedical imaging poses a number of
challenges for deep learning. Datasets are typically small,
annotations can be sparse, and images are often high-dimensional, multimodal and multi-channel. Techniques like
transfer learning, heavy dataset augmentation and the use of
multi-view and multi-stream architectures are more common
than in the natural image domain. Furthermore, high model
sensitivity and specificity can translate directly into clinical
value. Thus, prediction evaluation, uncertainty estimation
and model interpretation methods are also of great importance
in this domain (see Discussion). Finally, there is a need for
better pathologist–computer interaction techniques that will
allow combining the power of deep learning methods with
human expertise and lead to better-informed decisions for
patient treatment and care.
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well to 3D analogues, while requiring much less training
time, especially on augmented training sets. Another advantage of 2D and 2.5D networks is the wider availability of
pre-trained models. However, reducing the dimensionality
is not always helpful. Nie et al. [62] showed that multimodal,
multi-channel 3D deep architecture was successful at learning
high-level brain tumour appearance features jointly from
MRI, functional MRI and diffusion MRI images, outperforming single-modality or 2D models. Overall, the variety of
modalities, properties and sizes of training sets, the dimensionality of input and the importance of end goals in
medical image analysis are provoking a development of
specialized deep neural network architectures, training and
validation protocols, and input representations that are not
characteristic of widely-studied natural images.
Predictions from deep neural networks can be evaluated
for use in workflows that also incorporate human experts. In
a large dataset of mammography images, Kooi et al. [63]
demonstrated that deep neural networks outperform a
traditional computer-aided diagnosis system at low sensitivity and perform comparably at high sensitivity. They also
compared network performance to certified screening radiologists on a patch level and found no significant difference
between the network and the readers. However, using deep
methods for clinical practice is challenged by the difficulty of
assigning a level of confidence to each prediction. Leibig et al.
[49] estimated the uncertainty of deep networks for diabetic
retinopathy diagnosis by linking dropout networks with
approximate Bayesian inference. Techniques that assign confidences to each prediction should aid physician–computer
interactions and improve uptake by physicians.
Systems to aid in the analysis of histology slides are also
promising use cases for deep learning [64]. Ciresan et al. [27]
developed one of the earliest approaches for histology
slides, winning the 2012 International Conference on Pattern
Recognition’s Contest on Mitosis Detection while achieving
human-competitive accuracy. In more recent work, Wang
et al. [65] analysed stained slides of lymph node slices to identify cancers. On this task, a pathologist has about a 3% error rate.
The pathologist did not produce any false positives but did
have a number of false negatives. The algorithm had about
twice the error rate of a pathologist, but the errors were not
strongly correlated. Combining pre-trained deep network
architectures with multiple augmentation techniques enabled
accurate detection of breast cancer from a very small set of histology images with less than 100 images per class [66]. In this
area, these algorithms may be ready to be incorporated into
existing tools to aid pathologists and reduce the false negative
rate. Ensembles of deep learning and human experts may help
overcome some of the challenges presented by data limitations.
One source of training examples with rich phenotypical
annotations is the EHR. Billing information in the form of ICD
codes are simple annotations but phenotypic algorithms can
combine laboratory tests, medication prescriptions and patient
notes to generate more reliable phenotypes. Recently, Lee et al.
[67] developed an approach to distinguish individuals with
age-related macular degeneration from control individuals.
They trained a deep neural network on approximately 100 000
images extracted from structured EHRs, reaching greater than
93% accuracy. The authors used their test set to evaluate when
to stop training. In other domains, this has resulted in a minimal
change in the estimated accuracy [68], but we recommend the
use of an independent test set whenever feasible.
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Figure 2. Deep learning applications, tasks and models based on NLP perspectives.
recent years. The main tasks in biological and clinical text
mining include, but are not limited to, named entity recognition (NER), relation/event extraction and information
retrieval (figure 2). Deep learning is appealing in this domain
because of its competitive performance versus traditional
methods and ability to overcome challenges in feature
engineering. Relevant applications can be stratified by the
application domain (biomedical literature versus clinical
notes) and the actual task (e.g. concept or relation extraction).
NER is a task of identifying text spans that refer to a biological concept of a specific class, such as disease or chemical,
in a controlled vocabulary or ontology. NER is often needed
as a first step in many complex text mining systems. The current state-of-the-art methods typically reformulate the task as
a sequence labelling problem and use conditional random
fields [75– 77]. In recent years, word embeddings that contain
rich latent semantic information of words have been widely
used to improve the NER performance. Liu et al. [78] studied
the effect of word embeddings on drug name recognition and
compared them with traditional semantic features. Tang et al.
[79] investigated word embeddings in the gene, DNA and
cell line mention detection tasks. Moreover, Wu et al. [80]
examined the use of neural word embeddings for clinical
abbreviation disambiguation. Liu et al. [81] exploited taskoriented resources to learn word embeddings for clinical
abbreviation expansion.
Relation extraction involves detecting and classifying
semantic relationships between entities from the literature.
At present, kernel methods or feature-based approaches are
commonly applied [82–84]. Deep learning can relieve the feature sparsity and engineering problems. Some studies focused
on jointly extracting biomedical entities and relations simultaneously [85,86], while others applied deep learning on
relation classification given the relevant entities. For example,
both multi-channel dependency-based CNNs [87] and shortest
path-based CNNs [88,89] are well suited for sentence-based
protein–protein extraction. Jiang et al. [90] proposed a biomedical domain-specific word embedding model to reduce the
manual labour of designing semantic representation for the
same task. Gu et al. [91] employed a maximum-entropy
model and a CNN model for chemical-induced disease relation
extraction at the inter- and intra-sentence level, respectively.
For drug–drug interactions, Zhao et al. [92] used a CNN that
employs word embeddings with the syntactic information
of a sentence as well as features of part-of-speech tags and
dependency trees. Asada et al. [93] experimented with an
attention CNN, and Yi et al. [94] proposed an RNN model

with multiple attention layers. In both cases, it is a single
model with attention mechanism, which allows the decoder
to focus on different parts of the source sentence. As a result,
it does not require dependency parsing or training multiple
models. Both attention CNN and RNN have comparable
results, but the CNN model has an advantage in that it can
be easily computed in parallel, hence making it faster with
recent graphics processing units (GPUs).
For biotopes event extraction, Li et al. [95] employed CNNs
and distributed representation, while Mehryary et al. [96] used
long short-term memory (LSTM) networks to extract complicated relations. Li et al. [97] applied word embedding to
extract complete events from the biomedical text and achieved
results comparable to the state-of-the-art systems. There are
also approaches that identify event triggers rather than the
complete event [98,99]. Taken together, deep learning models
outperform traditional kernel methods or feature-based
approaches by 1–5% in f-score. Among various deep learning
approaches, CNNs stand out as the most popular model both
in terms of computational complexity and performance,
while RNNs have achieved continuous progress.
Information retrieval is a task of finding relevant text that
satisfies an information need from within a large document
collection. While deep learning has not yet achieved the
same level of success in this area as seen in others, the
recent surge of interest and work suggest that this may be
quickly changing. For example, Mohan et al. [100] described
a deep learning approach to modelling the relevance of a
document’s text to a query, which they applied to the entire
biomedical literature [100].
To summarize, deep learning has shown promising results
in many biomedical text mining tasks and applications. However, to realize its full potential in this domain, either large
amounts of labelled data or technical advancements in current
methods coping with limited labelled data are required.

2.3. Electronic health records
EHR data include substantial amounts of free text, which
remains challenging to approach [101]. Often, researchers
developing algorithms that perform well on specific tasks
must design and implement domain-specific features [102].
These features capture unique aspects of the literature being
processed. Deep learning methods are natural feature constructors. In recent work, Chalapathy et al. evaluated the extent to
which deep learning methods could be applied on top of generic features for domain-specific concept extraction [103]. They
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been used for both unsupervised feature construction and
supervised prediction. Early work by Lasko et al. [114], combined sparse autoencoders and Gaussian processes to
distinguish gout from leukaemia from uric acid sequences.
Later work showed that unsupervised feature construction of
many features via denoising autoencoder neural networks
could dramatically reduce the number of labelled examples
required for subsequent supervised analyses [115]. In addition,
it pointed towards features learned during unsupervised training being useful for visualizing and stratifying subgroups of
patients within a single disease. In a concurrent large-scale
analysis of EHR data from 700 000 patients, Miotto et al. [116]
used a deep denoising autoencoder architecture applied to
the number and co-occurrence of clinical events to learn a representation of patients (DeepPatient). The model was able to
predict disease trajectories within 1 year with over 90% accuracy, and patient-level predictions were improved by up to
15% when compared to other methods. Choi et al. [117]
attempted to model the longitudinal structure of EHRs with
an RNN to predict future diagnosis and medication prescriptions on a cohort of 260 000 patients followed for 8 years
(Doctor AI). Pham et al. [118] built upon this concept by
using an RNN with an LSTM architecture enabling explicit
modelling of patient trajectories through the use of memory
cells. The method, DeepCare, performed better than shallow
models or plain RNN when tested on two independent cohorts
for its ability to predict disease progression, intervention recommendation and future risk prediction. Nguyen et al. [119]
took a different approach and used word embeddings from
EHRs to train a CNN that could detect and pool local clinical
motifs to predict unplanned readmission after six months,
with performance better than the baseline method (Deepr).
Razavian et al. [120] used a set of 18 common laboratory tests
to predict disease onset using both CNN and LSTM architectures and demonstrated an improvement over baseline
regression models. However, numerous challenges including
data integration ( patient demographics, family history, laboratory tests, text-based patient records, image analysis, genomic
data) and better handling of streaming temporal data with
many features will need to be overcome before we can fully
assess the potential of deep learning for this application area.
Still, recent work has also revealed domains in which deep
networks have proven superior to traditional methods. Survival analysis models the time leading to an event of interest
from a shared starting point, and in the context of EHR data,
often associates these events to subject covariates. Exploring
this relationship is difficult, however, given that EHR data
types are often heterogeneous, covariates are often missing
and conventional approaches require the covariate–event
relationship be linear and aligned to a specific starting point
[121]. Early approaches, such as the Faraggi–Simon feedforward network, aimed to relax the linearity assumption,
but performance gains were lacking [122]. Katzman et al.
[123] in turn developed a deep implementation of the Faraggi–Simon network that, in addition to outperforming Cox
regression, was capable of comparing the risk between a
given pair of treatments, thus potentially acting as recommender system. To overcome the remaining difficulties, researchers
have turned to deep exponential families, a class of latent generative models that are constructed from any type of
exponential family distributions [124]. The result was a deep
survival analysis model capable of overcoming challenges
posed by missing data and heterogeneous data types, while
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found that performance was in line with, but lower than the
best domain-specific method [103]. This raises the possibility
that deep learning may impact the field by reducing the
researcher time and cost required to develop specific solutions,
but it may not always lead to performance increases.
In recent work, Yoon et al. [104] analysed simple features
using deep neural networks and found that the patterns recognized by the algorithms could be re-used across tasks. Their
aim was to analyse the free text portions of pathology reports
to identify the primary site and laterality of tumours. The
only features the authors supplied to the algorithms were
unigrams (counts for single words) and bigrams (counts for
two-word combinations) in a free text document. They subset
the full set of words and word combinations to the 400 most
common. The machine learning algorithms that they employed
(naive Bayes, logistic regression and deep neural networks) all
performed relatively similarly on the task of identifying the
primary site. However, when the authors evaluated the more
challenging task, evaluating the laterality of each tumour, the
deep neural network outperformed the other methods. Of particular interest, when the authors first trained a neural network
to predict the primary site and then repurposed those features
as a component of a secondary neural network trained to predict laterality, the performance was higher than a lateralitytrained neural network. This demonstrates how deep learning
methods can repurpose features across tasks, improving overall predictions as the field tackles new challenges. The
Discussion further reviews this type of transfer learning.
Several authors have created reusable feature sets for medical terminologies using NLP and neural embedding models, as
popularized by word2vec [105]. Minarro-Giménez et al. [106]
applied the word2vec deep learning toolkit to medical corpora
and evaluated the efficiency of word2vec in identifying properties of pharmaceuticals based on mid-sized, unstructured
medical text corpora without any additional background
knowledge. A goal of learning terminologies for different entities in the same vector space is to find relationships between
different domains (e.g. drugs and the diseases they treat). It
is difficult for us to provide a strong statement on the broad utility of these methods. Manuscripts in this area tend to compare
algorithms applied to the same data but lack a comparison
against overall best practices for one or more tasks addressed
by these methods. Techniques have been developed for free
text medical notes [107], ICD and National Drug Codes
[108,109] and claims data [110]. Methods for neural embeddings learned from EHRs have at least some ability to predict
disease–disease associations and implicate genes with a statistical association with a disease [111], but the evaluations
performed did not differentiate between simple predictions
(i.e. the same disease in different sites of the body) and nonintuitive ones. Jagannatha & Yu [112] further employed a
bidirectional LSTM structure to extract adverse drug events
from EHRs, and Lin et al. [113] investigated using CNNs to
extract temporal relations. While promising, a lack of rigorous
evaluation of the real-world utility of these kinds of features
makes current contributions in this area difficult to evaluate.
Comparisons need to be performed to examine the true utility
against leading approaches (i.e. algorithms and data) as
opposed to simply evaluating multiple algorithms on the
same potentially limited dataset.
Identifying consistent subgroups of individuals and individual health trajectories from clinical tests is also an active
area of research. Approaches inspired by deep learning have
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2.4.1. Generating ground-truth labels can be expensive or
impossible
A dearth of true labels is perhaps among the biggest obstacles
for EHR-based analyses that employ machine learning. Popular deep learning (and other machine learning) methods are
often used to tackle classification tasks and thus require
ground-truth labels for training. For EHRs, this can mean
that researchers must hire multiple clinicians to manually
read and annotate individual patients’ records through a process called chart review. This allows researchers to assign
‘true’ labels, i.e. those that match our best available knowledge.
Depending on the application, sometimes the features constructed by algorithms also need to be manually validated
and interpreted by clinicians. This can be time-consuming
and expensive [127]. Because of these costs, much of this
research, including the work cited in this review, skips the process of expert review. Clinicians’ skepticism for research
without expert review may greatly dampen their enthusiasm
for the work and consequently reduce its impact. To date,
even well-resourced large national consortia have been challenged by the task of acquiring enough expert-validated
labelled data. For instance, in the eMERGE consortia and
PheKB database [128], most samples with expert validation
contain only 100–300 patients. These datasets are quite small
even for simple machine learning algorithms. The challenge
is greater for deep learning models with many parameters.
While unsupervised and semi-supervised approaches can
help with small sample sizes, the field would benefit greatly
from large collections of anonymized records in which a substantial number of records have undergone expert review.
This challenge is not unique to EHR-based studies. Work on
medical images, omics data in applications for which detailed
metadata are required, and other applications for which labels
are costly to obtain will be hampered as long as abundant
curated data are unavailable.
Successful approaches to date in this domain have sidestepped this challenge by making methodological choices
that either reduce the need for labelled examples or use transformations to training data to increase the number of times it
can be used before overfitting occurs. For example, the unsupervised and semi-supervised methods that we have
discussed reduce the need for labelled examples [115]. The

2.4.2. Data sharing is hampered by standardization and privacy
considerations
To construct the types of very large datasets that deep learning methods thrive on, we need robust sharing of large
collections of data. This is, in part, a cultural challenge. We
touch on this challenge in the Discussion section. Beyond
the cultural hurdles around data sharing, there are also technological and legal hurdles related to sharing individual
health records or deep models built from such records. This
subsection deals primarily with these challenges.
EHRs are designed chiefly for clinical, administrative and
financial purposes, such as patient care, insurance and billing
[134]. Science is at best a tertiary priority, presenting challenges to EHR-based research, in general, and to deep
learning research, in particular. Although there is significant
work in the literature around EHR data quality and the
impact on research [135], we focus on three types of
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2.4. Challenges and opportunities in patient
categorization

anchor and learn framework [129] uses expert knowledge to
identify high-confidence observations from which labels can
be inferred. If transformations are available that preserve the
meaningful content of the data, the adversarial and augmented
training techniques discussed above can reduce overfitting.
While these can be easily imagined for certain methods
that operate on images, it is more challenging to figure out
equivalent transformations for a patient’s clinical test results.
Consequently, it may be hard to employ such training
examples with other applications. Finally, approaches that
transfer features can also help use valuable training data
most efficiently. Rajkomar et al. [58] trained a deep neural network using generic images before tuning using only radiology
images. Datasets that require many of the same types of features might be used for initial training, before fine-tuning
takes place with the more sparse biomedical examples.
Though the analysis has not yet been attempted, it is possible
that analogous strategies may be possible with EHRs. For
example, features learned from the EHR for one type of clinical
test (e.g. a decrease over time in a laboratory value) may transfer across phenotypes. Methods to accomplish more with little
high-quality labelled data arose in other domains and may also
be adapted to this challenge, e.g. data programming [130].
In data programming, noisy automated labelling functions
are integrated.
Numerous commentators have described data as the new
oil [131,132]. The idea behind this metaphor is that data are
available in large quantities, valuable once refined, and this
underlying resource will enable a data-driven revolution in
how work is done. Contrasting with this perspective,
Ratner et al. [133] described labelled training data, instead
of data, as ‘The New New Oil’. In this framing, data are abundant and not a scarce resource. Instead, new approaches to
solving problems arise when labelled training data become
sufficient to enable them. Based on our review of research
on deep learning methods to categorize disease, the latter
framing rings true.
We expect improved methods for domains with limited
data to play an important role if deep learning is going to
transform how we categorize states of human health. We
do not expect that deep learning methods will replace
expert review. We expect them to complement expert
review by allowing more efficient use of the costly practice
of manual annotation.
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uncovering nonlinear relationships between covariates and
failure time. They showed their model more accurately stratified patients as a function of disease-risk score compared to
the current clinical implementation.
There is a computational cost for these methods, however,
when compared to traditional, non-neural network
approaches. For the exponential family models, despite their
scalability [125], an important question for the investigator is
whether he or she is interested in estimates of posterior uncertainty. Given that these models are effectively Bayesian neural
networks, much of their utility simplifies to whether a Bayesian
approach is warranted for a given increase in computational
cost. Moreover, as with all variational methods, future work
must continue to explore just how well the posterior distributions are approximated, especially as model complexity
increases [126].
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Several technological solutions have been proposed in
this direction, allowing access to sensitive data satisfying
privacy and legal concerns. Software like DataShield [148]
and ViPAR [149], although not EHR-specific, allow querying
and combining of datasets and calculation of summary statistics across remote sites by ‘taking the analysis to the data’.
The computation is carried out at the remote site. Conversely,
the EH4CR project [141] allows analysis of private data by
use of an inter-mediation layer that interprets remote queries
across internal formats and datastores and returns the results
in a de-identified standard form, thus giving real-time consistent but secure access. Continuous analysis [150] can
allow reproducible computing on private data. Using such
techniques, intermediate results can be automatically tracked
and shared without sharing the original data. While none of
these have been used in deep learning, the potential is there.
Even without sharing data, algorithms trained on confidential patient data may present security risks or accidentally
allow for the exposure of individual-level patient data.
Tramer et al. [151] showed the ability to steal trained
models via public application programming interfaces
(APIs). Dwork & Roth [152] demonstrate the ability to expose
individual-level information from accurate answers in a
machine learning model. Attackers can use similar attacks to
find out if a particular data instance was present in the original
training set for the machine learning model [153], in this case,
whether a person’s record was present. To protect against these
attacks, Simmons et al. [154] developed the ability to perform
genome-wide association studies in a differentially private
manner, and Abadi et al. [155] show the ability to train deep
learning classifiers under the differential privacy framework.
These attacks also present a potential hazard for
approaches that aim to generate data. Choi et al. [156] propose
generative adversarial neural networks (GANs) as a tool to
make sharable EHR data, and Esteban et al. [157] showed
that recurrent GANs could be used for time-series data. However, in both cases the authors did not take steps to protect
the model from such attacks. There are approaches to protect
models, but they pose their own challenges. Training in a differentially private manner provides a limited guarantee that
an algorithm’s output will be equally likely to occur regardless of the participation of any one individual. The limit is
determined by parameters which provide a quantification
of privacy. Beaulieu-Jones et al. [158] demonstrated the
ability to generate data that preserved properties of the
SPRINT clinical trial with GANs under the differential privacy framework. Both Beaulieu-Jones et al. and Esteban et al.
train models on synthetic data generated under differential
privacy and observe performance from a transfer learning
evaluation that is only slightly below models trained on the
original, real data. Taken together, these results suggest that
differentially private GANs may be an attractive way to
generate sharable datasets for downstream reanalysis.
Federated learning [159] and secure aggregations [160] are
complementary approaches that reinforce differential privacy. Both aim to maintain privacy by training deep learning
models from decentralized data sources such as personal
mobile devices without transferring actual training instances.
This is becoming of increasing importance with the rapid
growth of mobile health applications. However, the training
process in these approaches places constraints on the algorithms used and can make fitting a model substantially
more challenging. It can be trivial to train a model without
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challenges: local bias, wider standards and legal issues. Note
these problems are not restricted to EHRs but can also apply
to any large biomedical dataset, e.g. clinical trial data.
Even within the same healthcare system, EHRs can be
used differently [136,137]. Individual users have unique
documentation and ordering patterns, with different departments and different hospitals having different priorities that
code patients and introduce missing data in a non-random
fashion [138]. Patient data may be kept across several ‘silos’
within a single health system (e.g. separate nursing documentation, registries, etc.). Even the most basic task of matching
patients across systems can be challenging due to data
entry issues [139]. The situation is further exacerbated by
the ongoing introduction, evolution and migration of
EHR systems, especially where reorganized and acquired
healthcare facilities have to merge. Furthermore, even the
ostensibly least-biased data type, laboratory measurements,
can be biased based by both the healthcare process and
patient health state [140]. As a result, EHR data can be less
complete and less objective than expected.
In the wider picture, standards for EHRs are numerous
and evolving. Proprietary systems, indifferent and scattered
use of health information standards, and controlled terminologies makes combining and comparison of data across
systems challenging [141]. Further diversity arises from variation in languages, healthcare practices and demographics.
Merging EHRs gathered in different systems (and even
under different assumptions) is challenging [142].
Combining or replicating studies across systems thus
requires controlling for both the above biases and dealing
with mismatching standards. This has the practical effect of
reducing cohort size, limiting statistical significance, preventing the detection of weak effects [143], and restricting the
number of parameters that can be trained in a model. Furthermore, rule-based algorithms have been popular in EHR-based
research, but because these are developed at a single institution
and trained with a specific patient population, they do not
transfer easily to other healthcare systems [144]. Genetic
studies using EHR data are subject to even more bias, as the
differences in population ancestry across health centres (e.g.
proportion of patients with African or Asian ancestry) can
affect algorithm performance. For example, Wiley et al. [145]
showed that warfarin dosing algorithms often under-perform
in African Americans, illustrating that some of these issues
are unresolved even at a treatment best practices level. Lack
of standardization also makes it challenging for investigators
skilled in deep learning to enter the field, as numerous data
processing steps must be performed before algorithms
are applied.
Finally, even if data were perfectly consistent and compatible across systems, attempts to share and combine EHR data
face considerable legal and ethical barriers. Patient privacy
can severely restrict the sharing and use of EHR data [146].
Here again, standards are heterogeneous and evolving, but
often EHR data cannot be exported or even accessed directly
for research purposes without appropriate consent. In the
USA, research use of EHR data is subject both to the
Common Rule and the Health Insurance Portability and
Accountability Act. Ambiguity in the regulatory language
and individual interpretation of these rules can hamper
use of EHR data [147]. Once again, this has the effect
of making data gathering more laborious and expensive,
reducing sample size and study power.
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In April 2016, the European Union adopted new rules regarding the use of personal information, the General Data
Protection Regulation [161]. A component of these rules can
be summed up by the phrase ‘right to an explanation’.
Those who use machine learning algorithms must be able
to explain how a decision was reached. For example, a clinician treating a patient who is aided by a machine learning
algorithm may be expected to explain decisions that use
the patient’s data. The new rules were designed to target categorization or recommendation systems, which inherently
profile individuals. Such systems can do so in ways that are
discriminatory and unlawful.
As datasets become larger and more complex, we may
begin to identify relationships in data that are important for
human health but difficult to understand. The algorithms
described in this review and others like them may become
highly accurate and useful for various purposes, including
within medical practice. However, to discover and avoid
discriminatory applications it will be important to consider
interpretability alongside accuracy. A number of properties
of genomic and healthcare data will make this difficult.
First, research samples are frequently non-representative of
the general population of interest; they tend to be disproportionately sick [162], male [163] and European in ancestry [164].
One well-known consequence of these biases in genomics is
that penetrance is consistently lower in the general population
than would be implied by case–control data, as reviewed in
[162]. Moreover, real genetic associations found in one population may not hold in other populations with different
patterns of linkage disequilibrium (even when population stratification is explicitly controlled for [165]). As a result, many
genomic findings are of limited value for people of non-European ancestry [164] and may even lead to worse treatment
outcomes for them. Methods have been developed for mitigating some of these problems in genomic studies [162,165], but it
is not clear how easily they can be adapted for deep models that
are designed specifically to extract subtle effects from highdimensional data. For example, differences in the equipment
that tended to be used for cases versus controls have led to
spurious genetic findings (e.g. Sebastiani et al.’s retraction
[166]). In some contexts, it may not be possible to correct for
all of these differences to the degree that a deep network is
unable to use them. Moreover, the complexity of deep networks makes it difficult to determine when their predictions
are likely to be based on such nominally irrelevant features
of the data (called ‘leakage’ in other fields [167]). When we

2.4.4. Applications of deep learning to longitudinal analysis
The longitudinal analysis follows a population across time,
for example, prospectively from birth or from the onset of
particular conditions. In large patient populations, longitudinal analyses such as the Framingham Heart Study [171] and
the Avon Longitudinal Study of Parents and Children [172]
have yielded important discoveries about the development
of disease and the factors contributing to health status. Yet, a
common practice in EHR-based research is to take a snapshot
at a point in time and convert patient data to a traditional
vector for machine learning and statistical analysis. This results
in loss of information as timing and order of events can provide
insight into a patient’s disease and treatment [173]. Efforts to
model sequences of events have shown promise [174] but
require exceedingly large patient sizes due to discrete combinatorial bucketing. Lasko et al. [114] used autoencoders on
longitudinal sequences of serum uric acid measurements to
identify population subtypes. More recently, deep learning
has shown promise working with both sequences (CNNs)
[175] and the incorporation of past and current state (RNNs,
LSTMs) [118]. This may be a particular area of opportunity
for deep neural networks. The ability to recognize relevant
sequences of events from a large number of trajectories requires
powerful and flexible feature construction methods—an area in
which deep neural networks excel.

3. Deep learning to study the fundamental
biological processes underlying
human disease
The study of cellular structure and core biological processes—
transcription, translation, signalling, metabolism, etc.—in
humans and model organisms will greatly impact our understanding of human disease over the long horizon [176].
Predicting how cellular systems respond to environmental
perturbations and are altered by genetic variation remain
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2.4.3. Discrimination and ‘right to an explanation’ laws

are not careful with our data and models, we may inadvertently say more about the way the data were collected (which
may involve a history of unequal access and discrimination)
than about anything of scientific or predictive value. This fact
can undermine the privacy of patient data [167] or lead to
severe discriminatory consequences [168].
There is a small but growing literature on the prevention
and mitigation of data leakage [167], as well as a closely
related literature on discriminatory model behaviour [169],
but it remains difficult to predict when these problems will
arise, how to diagnose them and how to resolve them in practice. There is even disagreement about which kinds of
algorithmic outcomes should be considered discriminatory
[170]. Despite the difficulties and uncertainties, machine
learning practitioners (and particularly those who use deep
neural networks, which are challenging to interpret) must
remain cognizant of these dangers and make every effort to
prevent harm from discriminatory predictions. To reach
their potential in this domain, deep learning methods will
need to be interpretable (see Discussion). Researchers need
to consider the extent to which biases may be learned by
the model and whether or not a model is sufficiently interpretable to identify bias. We discuss the challenge of model
interpretability more thoroughly in Discussion.

rsif.royalsocietypublishing.org

differential privacy, but quite difficult to train one within the
differential privacy framework [158]. This problem can be
particularly pronounced with small sample sizes.
While none of these problems are insurmountable or
restricted to deep learning, they present challenges that
cannot be ignored. Technical evolution in EHRs and data
standards will doubtless ease—although not solve—the problems of data sharing and merging. More problematic are the
privacy issues. Those applying deep learning to the domain
should consider the potential of inadvertently disclosing the
participants’ identities. Techniques that enable training on
data without sharing the raw data may have a part to play.
Training within a differential privacy framework may often
be warranted.
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Gene expression technologies characterize the abundance
of many thousands of RNA transcripts within a given organism, tissue or cell. This characterization can represent
the underlying state of the given system and can be used to
study heterogeneity across samples as well as how the
system reacts to perturbation. While gene expression measurements were traditionally made by quantitative polymerase
chain reaction, low-throughput fluorescence-based methods
and microarray technologies, the field has shifted in recent
years to primarily performing RNA sequencing (RNA-seq) to
catalogue whole transcriptomes. As RNA-seq continues to
fall in price and rise in throughput, sample sizes will increase
and training deep models to study gene expression will
become even more useful.
Already several deep learning approaches have been
applied to gene expression data with varying aims. For
instance, many researchers have applied unsupervised deep
learning models to extract meaningful representations of
gene modules or sample clusters. Denoising autoencoders
have been used to cluster yeast expression microarrays into
known modules representing cell cycle processes [179] and
to stratify yeast strains based on chemical and mutational
perturbations [180]. Shallow (one hidden layer) denoising
autoencoders have also been fruitful in extracting biological
insight from thousands of Pseudomonas aeruginosa experiments
[181,182] and in aggregating features relevant to specific
breast cancer subtypes [26]. These unsupervised approaches
applied to gene expression data are powerful methods for
identifying gene signatures that may otherwise be overlooked.
An additional benefit of unsupervised approaches is that
ground-truth labels, which are often difficult to acquire or are
incorrect, are non-essential. However, the genes that have
been aggregated into features must be interpreted carefully.
Attributing each node to a single specific biological function

3.2. Splicing
Pre-mRNA transcripts can be spliced into different isoforms by
retaining or skipping subsets of exons or including parts
of introns, creating enormous spatio-temporal flexibility to
generate multiple distinct proteins from a single gene. This
remarkable complexity can lend itself to defects that underlie
many diseases. For instance, splicing mutations in the lamin
A (LMNA) gene can lead to specific variants of dilated cardiomyopathy and limb-girdle muscular dystrophy [187]. A recent
study found that quantitative trait loci that affect splicing in
lymphoblastoid cell lines are enriched within risk loci for
schizophrenia, multiple sclerosis and other immune diseases,
implicating mis-splicing as a more widespread feature of
human pathologies than previously thought [188]. Therapeutic
strategies that aim to modulate splicing are also currently
being considered for disorders such as Duchenne muscular
dystrophy and spinal muscular atrophy [187].
Sequencing studies routinely return thousands of unannotated variants, but which cause functional changes in splicing
and how are those changes manifested? Prediction of a ‘splicing code’ has been a goal of the field for the past decade.
Initial machine learning approaches used a naive Bayes
model and a two-layer Bayesian neural network with
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risks over-interpreting models. Batch effects could cause
models to discover non-biological features, and downstream
analyses should take this into consideration.
Deep learning approaches are also being applied to gene
expression prediction tasks. For example, a deep neural
network with three hidden layers outperformed linear
regression in inferring the expression of over 20 000 target
genes based on a representative, well-connected set of about
1000 landmark genes [183]. However, while the deep learning
model outperformed existing algorithms in nearly every scenario, the model still displayed poor performance. The paper
was also limited by computational bottlenecks that required
data to be split randomly into two distinct models and trained
separately. It is unclear how much performance would have
increased if not for computational restrictions.
Epigenomic data, combined with deep learning, may
have sufficient explanatory power to infer gene expression.
For instance, the DeepChrome CNN [184] improved the prediction accuracy of high or low gene expression from histone
modifications over existing methods. AttentiveChrome [185]
added a deep attention model to further enhance DeepChrome. Deep learning can also integrate different data
types. For example, Liang et al. [186] combined RBMs to integrate gene expression, DNA methylation and miRNA data to
define ovarian cancer subtypes. While these approaches are
promising, many convert gene expression measurements
to categorical or binary variables, thus ablating many complex gene expression signatures present in intermediate and
relative numbers.
Deep learning applied to gene expression data is still in its
infancy, but the future is bright. Many previously untestable
hypotheses can now be interrogated as deep learning enables
analysis of increasing amounts of data generated by new
technologies. For example, the effects of cellular heterogeneity on basic biology and disease aetiology can now be
explored by single-cell RNA-seq and high-throughput fluorescence-based imaging, techniques we discuss below that
will benefit immensely from deep learning approaches.
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daunting tasks. Deep learning offers new approaches for
modelling biological processes and integrating multiple types
of omic data [177], which could eventually help predict how
these processes are disrupted in disease. Recent work has
already advanced our ability to identify and interpret genetic
variants, study microbial communities and predict protein
structures, which also relates to the problems discussed in
the drug development section. In addition, unsupervised
deep learning has enormous potential for discovering novel
cellular states from gene expression, fluorescence microscopy
and other types of data that may ultimately prove to be
clinically relevant.
Progress has been rapid in genomics and imaging, fields
where important tasks are readily adapted to well-established
deep learning paradigms. One-dimensional CNNs and
RNNs are well suited for tasks related to DNA- and RNAbinding proteins, epigenomics and RNA splicing. Twodimensional CNNs are ideal for segmentation, feature extraction and classification in fluorescence microscopy images
[17]. Other areas, such as cellular signalling, are biologically
important but studied less-frequently to date, with some
exceptions [178]. This may be a consequence of data limitations or greater challenges in adapting neural network
architectures to the available data. Here, we highlight several
areas of investigation and assess how deep learning might
move these fields forward.

TFs are proteins that bind regulatory DNA in a sequencespecific manner to modulate the activation and repression
of gene transcription. High-throughput in vitro experimental
assays that quantitatively measure the binding specificity of
a TF to a large library of short oligonucleotides [196] provide
rich datasets to model the naked DNA sequence affinity of
individual TFs in isolation. However, in vivo TF binding is
affected by a variety of other factors beyond sequence affinity, such as competition and cooperation with other TFs,
TF concentration and chromatin state (chemical modifications
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to DNA and other packaging proteins that DNA is wrapped
around) [196]. TFs can thus exhibit highly variable binding
landscapes across the same genomic DNA sequence across
diverse cell types and states. Several experimental approaches
such as chromatin immunoprecipitation followed by sequencing (ChIP-seq) have been developed to profile in vivo
binding maps of TFs [196]. Large reference compendia of
ChIP-seq data are now freely available for a large collection
of TFs in a small number of reference cell states in humans
and a few other model organisms [197]. Owing to fundamental material and cost constraints, it is infeasible to perform
these experiments for all TFs in every possible cellular state
and species. Hence, predictive computational models of TF
binding are essential to understand gene regulation in diverse
cellular contexts.
Several machine learning approaches have been developed
to learn generative and discriminative models of TF binding
from in vitro and in vivo TF binding datasets that associate
collections of synthetic DNA sequences or genomic DNA
sequences to binary labels (bound/unbound) or continuous
measures of binding. The most common class of TF binding
models in the literature are those that only model the DNA
sequence affinity of TFs from in vitro and in vivo binding
data. The earliest models were based on deriving simple, compact, interpretable sequence motif representations such as
position weight matrices (PWMs) and other biophysically
inspired models [198–200]. These models were outperformed
by general k-mer-based models including support vector
machines (SVMs) with string kernels [201,202].
In 2015, Alipanahi et al. [203] developed DeepBind, the first
CNN to classify bound DNA sequences based on in vitro and
in vivo assays against random DNA sequences matched for
dinucleotide sequence composition. The convolutional layers
learn pattern detectors reminiscent of PWMs from a onehot encoding of the raw input DNA sequences. DeepBind
outperformed several state-of-the-art methods from the
DREAM5 in vitro TF-DNA motif recognition challenge [200].
Although DeepBind was also applied to RNA-binding proteins, in general, RNA binding is a separate problem [204]
and accurate models will need to account for RNA secondary
structure. Following DeepBind, several optimized convolutional and recurrent neural network architectures as well as
novel hybrid approaches that combine kernel methods with
neural networks have been proposed that further improve
performance [205–208]. Specialized layers and regularizers
have also been proposed to reduce parameters and learn
more robust models by taking advantage of specific properties of DNA sequences such as their reverse complement
equivalence [209,210].
While most of these methods learn independent models for
different TFs, in vivo multiple TFs compete or cooperate to
occupy DNA binding sites, resulting in complex combinatorial
co-binding landscapes. To take advantage of this shared
structure in in vivo TF binding data, multi-task neural network
architectures have been developed that explicitly share
parameters across models for multiple TFs [208,211,212].
Some of these multi-task models train and evaluate classification performance relative to an unbound background set of
regulatory DNA sequences sampled from the genome rather
than using synthetic background sequences with matched
dinucleotide composition.
The above-mentioned TF binding prediction models that
use only DNA sequences as inputs have a fundamental
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thousands of hand-derived sequence-based features to predict
the probability of exon skipping [189,190]. With the advent of
deep learning, more complex models provided better predictive accuracy [191,192]. Importantly, these new approaches
can take in multiple kinds of epigenomic measurements as
well as tissue identity and RNA-binding partners of splicing
factors. Deep learning is critical in furthering these kinds of
integrative studies where different data types and inputs interact in unpredictable (often nonlinear) ways to create higherorder features. Moreover, as in gene expression network analysis, interrogating the hidden nodes within neural networks
could potentially illuminate important aspects of splicing behaviour. For instance, tissue-specific splicing mechanisms
could be inferred by training networks on splicing data from
different tissues, then searching for common versus distinctive
hidden nodes, a technique employed by Qin et al. [193] for
tissue-specific transcription factor (TF) binding predictions.
A parallel effort has been to use more data with simpler
models. An exhaustive study using readouts of splicing for
millions of synthetic intronic sequences uncovered motifs
that influence the strength of alternative splice sites [194].
The authors built a simple linear model using hexamer motif
frequencies that successfully generalized to exon skipping. In
a limited analysis using single-nucleotide polymorphisms
(SNPs) from three genes, it predicted exon skipping with
three times the accuracy of an existing deep learning-based framework [191]. This case is instructive in that clever sources of
data, not just more descriptive models, are still critical.
We already understand how mis-splicing of a single gene
can cause diseases such as limb-girdle muscular dystrophy.
The challenge now is to uncover how genome-wide alternative
splicing underlies complex, non-Mendelian diseases such as
autism, schizophrenia, Type 1 diabetes and multiple sclerosis
[195]. As a proof of concept, Xiong et al. [191] sequenced five
autism spectrum disorder and 12 control samples, each with
an average of 42 000 rare variants, and identified mis-splicing
in 19 genes with neural functions. Such methods may one
day enable scientists and clinicians to rapidly profile thousands
of unannotated variants for functional effects on splicing and
nominate candidates for further investigation. Moreover,
these nonlinear algorithms can deconvolve the effects of multiple variants on a single splice event without the need to
perform combinatorial in vitro experiments. The ultimate goal
is to predict an individual’s tissue-specific, exon-specific
splicing patterns from their genome sequence and other
measurements to enable a new branch of precision diagnostics
that also stratifies patients and suggests targeted therapies to
correct splicing defects. However, to achieve this we expect
that methods to interpret the ‘black box’ of deep neural
networks and integrate diverse data sources will be required.
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3.4. Promoters and enhancers
3.4.1. From transcription factor binding to promoters
and enhancers
Multiple TFs act in concert to coordinate changes in gene
regulation at the genomic regions known as promoters and
enhancers. Each gene has an upstream promoter, essential for
initiating that gene’s transcription. The gene may also interact
with multiple enhancers, which can amplify transcription in
particular cellular contexts. These contexts include different
cell types in development or environmental stresses.
Promoters and enhancers provide a nexus where clusters
of TFs and binding sites mediate downstream gene
regulation, starting with transcription. The gold standard to
identify an active promoter or enhancer requires demonstrating its ability to affect transcription or other downstream
gene products. Even extensive biochemical TF binding data
has thus far proven insufficient on its own to accurately
and comprehensively locate promoters and enhancers. We
lack sufficient understanding of these elements to derive a
mechanistic ‘promoter code’ or ‘enhancer code’. But extensive
labelled data on promoters and enhancers lends itself to
probabilistic classification. The complex interplay of TFs
and chromatin leading to the emergent properties of promoter and enhancer activity seems particularly apt for
representation by deep neural networks.

3.4.2. Promoters
Despite decades of work, computational identification of promoters remains a stubborn problem [222]. Researchers have
used neural networks for promoter recognition as early as
1996 [223]. Recently, a CNN recognized promoter sequences
with sensitivity and specificity exceeding 90% [224]. Most
activity in computational prediction of regulatory regions, however, has moved to enhancer identification. Because one can
identify promoters with straightforward biochemical assays
[225,226], the direct rewards of promoter prediction alone have
decreased. But the reliable ground-truth provided by these
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It is worth noting that TF binding prediction methods in
the literature based on neural networks and other machine
learning approaches choose to sample the set of bound and
unbound sequences in a variety of different ways. These
choices and the choice of performance evaluation measures
significantly confound systematic comparison of model
performance (see Discussion).
Several methods have also been developed to interpret
neural network models of TF binding. Alipanahi et al. [203]
visualize convolutional filters to obtain insights into the
sequence preferences of TFs. They also introduced in silico
mutation maps for identifying important predictive nucleotides
in input DNA sequences by exhaustively forward propagating
perturbations to individual nucleotides to record the corresponding change in output prediction. Shrikumar et al. [221]
proposed efficient backpropagation-based approaches to simultaneously score the contribution of all nucleotides in an input
DNA sequence to an output prediction. Lanchantin et al. [206]
developed tools to visualize TF motifs learned from TF binding
site classification tasks. These and other general interpretation
techniques (see Discussion) will be critical to improve our
understanding of the biologically meaningful patterns learned
by deep learning models of TF binding.
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limitation. Because the DNA sequence of a genome is the
same across different cell types and states, a sequence-only
model of TF binding cannot predict different in vivo TF binding landscapes in new cell types not used during training.
One approach for generalizing TF binding predictions
to new cell types is to learn models that integrate DNA
sequence inputs with other cell-type-specific data modalities
that modulate in vivo TF binding such as surrogate measures
of TF concentration (e.g. TF gene expression) and chromatin state. Arvey et al. [213] showed that combining the
predictions of SVMs trained on DNA sequence inputs and
cell-type specific DNase-seq data, which measures genomewide chromatin accessibility, improved in vivo TF binding
prediction within and across cell types. Several ‘footprinting’-based methods have also been developed that learn to
discriminate bound from unbound instances of known canonical motifs of a target TF based on high-resolution footprint
patterns of chromatin accessibility that are specific to the
target TF [214]. However, the genome-wide predictive performance of these methods in new cell types and states has
not been evaluated.
Recently, a community challenge known as the ‘ENCODEDREAM in vivo TF Binding Site Prediction Challenge’ was
introduced to systematically evaluate the genome-wide performance of methods that can predict TF binding across
cell states by integrating DNA sequence and in vitro DNA
shape with cell-type-specific chromatin accessibility and gene
expression [215]. A deep learning model called FactorNet was
among the top three performing methods in the challenge
[216]. FactorNet uses a multimodal hybrid convolutional and
recurrent architecture that integrates DNA sequence with chromatin accessibility profiles, gene expression and evolutionary
conservation of sequence. It is worth noting that FactorNet
was slightly outperformed by an approach that does not use
neural networks [217]. This top ranking approach uses an
extensive set of curated features in a weighted variant of a
discriminative maximum conditional likelihood model in combination with a novel iterative training strategy and model
stacking. There appears to be significant room for improvement
because none of the current approaches for cross cell-type prediction explicitly account for the fact that TFs can co-bind with
distinct cofactors in different cell states. In such cases, sequence
features that are predictive of TF binding in one cell state may be
detrimental to predicting binding in another.
Singh et al. [218] developed transfer string kernels for
SVMs for cross-context TF binding. Domain adaptation
methods that allow training neural networks which are transferable between differing training and test set distributions of
sequence features could be a promising avenue going forward [219,220]. These approaches may also be useful for
transferring TF binding models across species.
Another class of imputation-based cross cell type in vivo
TF binding prediction methods leverage the strong correlation
between combinatorial binding landscapes of multiple TFs.
Given a partially complete panel of binding profiles of multiple TFs in multiple cell types, a deep learning method called
TFImpute learns to predict the missing binding profile of a
target TF in some target cell type in the panel based on the
binding profiles of other TFs in the target cell type and
the binding profile of the target TF in other cell types in the
panel [193]. However, TFImpute cannot generalize predictions
beyond the training panel of cell types and requires TF binding
profiles of related TFs.

assays makes promoter identification an appealing test bed for
deep learning approaches that can also identify enhancers.
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3.4.4. Promoter –enhancer interactions
In addition to the location of enhancers, identifying enhancer –
promoter interactions in three-dimensional space will provide
critical knowledge for understanding transcriptional regulation. SPEID used a CNN to predict these interactions with
only sequence and the location of putative enhancers and
promoters along a one-dimensional chromosome [232]. It
compared well to other methods using a full complement
of biochemical data from ChIP-seq and other epigenomic
methods. Of course, the putative enhancers and promoters
used were themselves derived from epigenomic methods.
But one could easily replace them with the output of one of
the enhancer or promoter prediction methods above.

3.5. MicroRNA binding
Prediction of miRNAs and miRNA targets is of great interest, as
they are critical components of gene regulatory networks
and are often conserved across great evolutionary distance
[233,234]. While many machine learning algorithms have
been applied to these tasks, they currently require extensive feature selection and optimization. For instance, one of the most
widely adopted tools for miRNA target prediction, TargetScan,

3.6. Protein secondary and tertiary structure
Proteins play fundamental roles in almost all biological processes, and understanding their structure is critical for basic
biology and drug development. UniProt currently has about
94 million protein sequences, yet fewer than 100 000 proteins
across all species have experimentally solved structures in
Protein Data Bank (PDB). As a result, computational structure
prediction is essential for a majority of proteins. However, this
is very challenging, especially when similar solved structures,
called templates, are not available in PDB. Over the past several
decades, many computational methods have been developed
to predict aspects of protein structure such as secondary structure, torsion angles, solvent accessibility, inter-residue contact
maps, disorder regions and side-chain packing. In recent
years, multiple deep learning architectures have been applied,
including DBNs, LSTMs, CNNs and deep convolutional neural
fields [31,238].
Here, we focus on deep learning methods for two representative sub-problems: secondary structure prediction and
contact map prediction. Secondary structure refers to local
conformation of a sequence segment, while a contact map
contains information on all residue–residue contacts. Secondary structure prediction is a basic problem and an almost
essential module of any protein structure prediction package.
Contact prediction is much more challenging than secondary
structure prediction, but it has a much larger impact on tertiary structure prediction. In recent years, the accuracy of
contact prediction has greatly improved [29,239–241].
One can represent protein secondary structure with three
different states (a-helix, b-strand and loop regions) or eight
finer-grained states. The accuracy of a three-state prediction
is called Q3, and accuracy of an eight-state prediction is
called Q8. Several groups [30,242,243] applied deep learning
to protein secondary structure prediction but were unable to
achieve significant improvement over the de facto standard
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Recognizing enhancers presents additional challenges.
Enhancers may be up to 1 000 000 bp away from the affected
promoter, and even within introns of other genes [227]. Enhancers do not necessarily operate on the nearest gene and may
affect multiple genes. Their activity is frequently tissue- or
context-specific. No biochemical assay can reliably identify
all enhancers. Distinguishing them from other regulatory
elements remains difficult, and some believe the distinction
somewhat artificial [228]. While these factors make the enhancer identification problem more difficult, they also make a
solution more valuable.
Several neural network approaches yielded promising
results in enhancer prediction. Both Basset [229] and DeepEnhancer [230] used CNNs to predict enhancers. DECRES used
a feed-forward neural network [231] to distinguish between
different kinds of regulatory elements, such as active enhancers and promoters. DECRES had difficulty distinguishing
between inactive enhancers and promoters. They also investigated the power of sequence features to drive classification,
finding that beyond CpG islands, few were useful.
Comparing the performance of enhancer prediction
methods illustrates the problems in using metrics created
with different benchmarking procedures. Both the Basset
and DeepEnhancer studies include comparisons to a baseline
SVM approach, gkm-SVM [202]. The Basset study reports
gkm-SVM attains a mean area under the precision-recall
curve (AUPR) of 0.322 over 164 cell types [229]. The DeepEnhancer study reports for gkm-SVM a dramatically different
AUPR of 0.899 on nine cell types [230]. This large difference
means it is impossible to directly compare the performance of
Basset and DeepEnhancer based solely on their reported
metrics. DECRES used a different set of metrics altogether.
To drive further progress in enhancer identification, we
must develop a common and comparable benchmarking
procedure (see Discussion).
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trained multiple linear regression models on 14 hand-curated
features including structural accessibility of the target site on
the mRNA, the degree of site conservation and predicted
thermodynamic stability of the miRNA–mRNA complex
[235]. Some of these features, including structural accessibility,
are imperfect or empirically derived. In addition, current
algorithms suffer from low specificity [236].
As in other applications, deep learning promises to
achieve equal or better performance in predictive tasks by
automatically engineering complex features to minimize an
objective function. Two recently published tools use different
recurrent neural network-based architectures to perform
miRNA and target prediction with solely sequence data as
input [236,237]. Though the results are preliminary and still
based on a validation set rather than a completely independent test set, they were able to predict microRNA target
sites with higher specificity and sensitivity than TargetScan.
Excitingly, these tools seem to show that RNNs can accurately align sequences and predict bulges, mismatches and
wobble base pairing without requiring the user to input secondary structure predictions or thermodynamic calculations.
Further incremental advances in deep learning for miRNA
and target prediction will likely be sufficient to meet the current needs of systems biologists and other researchers who
use prediction tools mainly to nominate candidates that are
then tested experimentally.

Complementing computational prediction approaches, cryoelectron microscopy (cryo-EM) allows near-atomic resolution
determination of protein models by comparing individual
electron micrographs [254]. Detailed structures require tens
of thousands of protein images [255]. Technological development has increased the throughput of image capture. New
hardware, such as direct electron detectors, has made largescale image production practical, while new software has
focused on rapid, automated image processing.
Some components of cryo-EM image processing remain
difficult to automate. For instance, in particle picking, micrographs are scanned to identify individual molecular images
that will be used in structure refinement. In typical applications, hundreds of thousands of particles are necessary to
determine a structure to near-atomic resolution, making
manual selection impractical [255]. Typical selection
approaches are semi-supervised; a user will select several particles manually, and these selections will be used to train a
classifier [256,257]. Now CNNs are being used to select particles in tools like DeepPicker [258] and DeepEM [259]. In
addition to addressing shortcomings from manual selection,
such as selection bias and poor discrimination of low-contrast
images, these approaches also provide a means of full automation. DeepPicker can be trained by reference particles from
other experiments with structurally unrelated macromolecules,
allowing for fully automated application to new samples.
Downstream of particle picking, deep learning is being
applied to other aspects of cryo-EM image processing. Statistical manifold learning has been implemented in the
software package ROME to classify selected particles and elucidate the different conformations of the subject molecule
necessary for accurate 3D structures [260]. These recent
tools highlight the general applicability of deep learning
approaches for image processing to increase the throughput
of high-resolution cryo-EM.

3.8. Protein –protein interactions
Protein –protein interactions (PPIs) are highly specific and
non-accidental physical contacts between proteins, which
occur for purposes other than generic protein production or
degradation [261]. Abundant interaction data have been generated in part thanks to advances in high-throughput
screening methods, such as yeast two-hybrid and affinitypurification with mass spectrometry. However, because
many PPIs are transient or dependent on biological context,
high-throughput methods can fail to capture a number of
interactions. The imperfections and costs associated with
many experimental PPI screening methods have motivated
an interest in high-throughput computational prediction.
Many machine learning approaches to PPI have focused on
text mining the literature [262,263], but these approaches can
fail to capture context-specific interactions, motivating de
novo PPI prediction. Early de novo prediction approaches
used a variety of statistical and machine learning tools on structural and sequential data, sometimes with reference to the
existing body of protein structure knowledge. In the context
of PPIs—as in other domains—deep learning shows promise
both for exceeding current predictive performance and for
circumventing limitations from which other approaches suffer.
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method PSIPRED [244], which uses two shallow feed-forward
neural networks. In 2014, Zhou & Troyanskaya [245] demonstrated that they could improve Q8 accuracy by using a deep
supervised and convolutional generative stochastic network.
In 2016, Wang et al. developed a DeepCNF model that
improved Q3 and Q8 accuracy as well as prediction of solvent
accessibility and disorder regions [31,238]. DeepCNF achieved
a higher Q3 accuracy than the standard maintained by
PSIPRED for more than 10 years. This improvement may be
mainly due to the ability of convolutional neural fields to capture long-range sequential information, which is important for
b-strand prediction. Nevertheless, the improvements in secondary structure prediction from DeepCNF are unlikely to
result in a commensurate improvement in tertiary structure
prediction because secondary structure mainly reflects
coarse-grained local conformation of a protein structure.
Protein contact prediction and contact-assisted folding
(i.e. folding proteins using predicted contacts as restraints)
represent a promising new direction for ab initio folding of
proteins without good templates in PDB. Coevolution analysis is effective for proteins with a very large number (more
than 1000) of sequence homologues [241], but fares poorly
for proteins without many sequence homologues. By combining coevolution information with a few other protein
features, shallow neural network methods such as MetaPSICOV [239] and CoinDCA-NN [246] have shown some
advantage over pure coevolution analysis for proteins with
few sequence homologues, but their accuracy is still far
from satisfactory. In recent years, deeper architectures have
been explored for contact prediction, such as CMAPpro
[247], DNCON [248] and PConsC [249]. However, blindly
tested in the well-known CASP competitions, these methods
did not show any advantage over MetaPSICOV [239].
Recently, Wang et al. [29] proposed the deep learning
method RaptorX-Contact, which significantly improves contact prediction over MetaPSICOV and pure coevolution
methods, especially for proteins without many sequence
homologues. It employs a network architecture formed by
one one-dimensional residual neural network and one 2D
residual neural network. Blindly tested in the latest CASP
competition (i.e. CASP12 [250]), RaptorX-Contact ranked
first in F1 score on free-modelling targets as well as the
whole set of targets. In CAMEO (which can be interpreted
as a fully automated CASP) [251], its predicted contacts
were also able to fold proteins with a novel fold and only
65– 330 sequence homologues. This technique also worked
well on membrane proteins even when trained on non-membrane proteins [252]. RaptorX-Contact performed better
mainly due to the introduction of residual neural networks
and exploitation of contact occurrence patterns by simultaneously predicting all the contacts in a single protein.
Taken together, ab initio folding is becoming much easier
with the advent of direct evolutionary coupling analysis and
deep learning techniques. We expect further improvements in
contact prediction for proteins with fewer than 1000 homologues by studying new deep network architectures. The
deep learning methods summarized above also apply to
interfacial contact prediction for protein complexes but may
be less effective because on average protein complexes have
fewer sequence homologues. Beyond secondary structure
and contact maps, we anticipate increased attention to predicting 3D protein structure directly from amino acid
sequence and single residue evolutionary information [253].
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An important type of PPI involves the immune system’s ability
to recognize the body’s own cells. The major histocompatibility
complex (MHC) plays a key role in regulating this process by
binding antigens and displaying them on the cell surface to
be recognized by T cells. Owing to its importance in immunity
and immune response, peptide–MHC binding prediction is a
useful problem in computational biology, and one that must
account for the allelic diversity in MHC-encoding gene region.
Shallow, feed-forward neural networks are competitive
methods and have made progress towards pan-allele and
pan-length peptide representations. Sequence alignment techniques are useful for representing variable-length peptides as
uniform-length features [268,269]. For pan-allelic prediction,
NetMHCpan [270,271] used a pseudo-sequence representation
of the MHC class I molecule, which included only polymorphic peptide contact residues. The sequences of the
peptide and MHC were then represented using both sparse
vector encoding and Blosum encoding, in which amino acids
are encoded by matrix score vectors. A comparable method
to the NetMHC tools is MHCflurry [272], a method which
shows superior performance on peptides of lengths other
than nine. MHCflurry adds placeholder amino acids to transform variable-length peptides to length 15 peptides. When
training the MHCflurry feed-forward neural network [273],
the authors imputed missing MHC-peptide binding affinities
using a Gibbs sampling method, showing that imputation

3.10. Protein –protein interaction networks and
graph analysis
Because interacting proteins are more likely to share a similar
function, the connectivity of a PPI network itself can be a
valuable information source for the prediction of protein
function [277]. To incorporate higher-order network information, it is necessary to find a lower-level embedding of
network structure that preserves this higher-order structure.
Rather than use hand-crafted network features, deep learning
shows promise for the automatic discovery of predictive
features within networks. For example, Navlakha [278]
showed that a deep autoencoder was able to compress a
graph to 40% of its original size, while being able to reconstruct 93% of the original graph’s edges, improving upon
standard dimension reduction methods. To achieve this,
each graph was represented as an adjacency matrix with
rows sorted in descending node degree order, then flattened
into a vector and given as input to the autoencoder. While the
activity of some hidden layers correlated with several popular hand-crafted network features such as k-core size and
graph density, this work showed that deep learning can effectively reduce graph dimensionality while retaining much of
its structural information.
An important challenge in PPI network prediction is the
task of combining different networks and types of networks.
Gligorijevic et al. [279] developed a multimodal deep autoencoder, deepNF, to find a feature representation common
among several different PPI networks. This common lowerlevel representation allows for the combination of various
PPI data sources towards a single predictive task. An SVM
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improves performance for datasets with roughly 100 or fewer
training examples. MHCflurry’s imputation method increases
its performance on poorly characterized alleles, making it competitive with NetMHCpan for this task. Kuksa et al. [274]
developed a shallow, higher-order neural network (HONN)
comprised both mean and covariance hidden units to capture
some of the higher-order dependencies between amino acid
locations. Pre-training this HONN with a semi-RBM, the
authors found that the performance of the HONN exceeded
that of a simple deep neural network, as well as that
of NetMHC.
Deep learning’s unique flexibility was recently leveraged
by Bhattacharya et al. [275], who used a gated RNN method
called MHCnuggets to overcome the difficulty of multiple
peptide lengths. Under this framework, they used smoothed
sparse encoding to represent amino acids individually.
Because MHCnuggets had to be trained for every MHC
allele, performance was far better for alleles with abundant,
balanced training data. Vang et al. [276] developed HLACNN, a method which maps amino acids onto a 15-dimensional vector space based on their context relation to other
amino acids before making predictions with a CNN. In a
comparison of several current methods, Bhattacharya et al.
found that the top methods—NetMHC, NetMHCpan,
MHCflurry and MHCnuggets—showed comparable performance, but large differences in speed. Convolutional
neural networks (in this case, HLA-CNN) showed comparatively poor performance, while shallow networks and
RNNs performed the best. They found that MHCnuggets—
the recurrent neural network—was by far the fastest-training
among the top performing methods.
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One of the key difficulties in applying deep learning techniques to binding prediction is the task of representing
peptide and protein sequences in a meaningful way. DeepPPI
[264] made PPI predictions from a set of sequence and composition protein descriptors using a two-stage deep neural
network that trained two subnetworks for each protein and
combined them into a single network. Sun et al. [265] applied
autocovariances, a coding scheme that returns uniform-size
vectors describing the covariance between physico-chemical
properties of the protein sequence at various positions. Wang
et al. [266] used deep learning as an intermediate step in PPI
prediction. They examined 70 amino acid protein sequences
from each of which they extracted 1260 features. A stacked
sparse autoencoder with two hidden layers was then used to
reduce feature dimensions and noisiness before a novel type
of classification vector machine made PPI predictions.
Beyond predicting whether or not two proteins interact,
Du et al. [267] employed a deep learning approach to predict
the residue contacts between two interacting proteins. Using
features that describe how similar a protein’s residue is relative to similar proteins at the same position, the authors
extracted uniform-length features for each residue in the
protein sequence. A stacked autoencoder took two such vectors as input for the prediction of contact between two
residues. The authors evaluated the performance of this
method with several classifiers and showed that a deep
neural network classifier paired with the stacked autoencoder
significantly exceeded classical machine learning accuracy.
Because many studies used predefined higher-level features, one of the benefits of deep learning—automatic
feature extraction—is not fully leveraged. More work is
needed to determine the best ways to represent raw protein
sequence information so that the full benefits of deep learning
as an automatic feature extractor can be realized.
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A field poised for dramatic revolution by deep learning is bioimage analysis. Thus far, the primary use of deep learning for
biological images has been for segmentation—that is, for the
identification of biologically relevant structures in images
such as nuclei, infected cells or vasculature—in fluorescence
or even brightfield channels [282]. Once the so-called regions
of interest have been identified, it is often straightforward to
measure biological properties of interest, such as fluorescence
intensities, textures and sizes. Given the dramatic successes
of deep learning in biological imaging, we simply refer to
articles that review recent advancements [17,282,283]. However, user-friendly tools must be developed for deep learning
to become commonplace for biological image segmentation.
We anticipate an additional paradigm shift in bioimaging
that will be brought about by deep learning: what if images
of biological samples, from simple cell cultures to threedimensional organoids and tissue samples, could be mined
for much more extensive biologically meaningful information
than is currently standard? For example, a recent study demonstrated the ability to predict lineage fate in haematopoietic cells
up to three generations in advance of differentiation [284]. In
biomedical research, most often biologists decide in advance
what feature to measure in images from their assay system.
Although classical methods of segmentation and feature
extraction can produce hundreds of metrics per cell in an
image, deep learning is unconstrained by human intuition
and can in theory extract more subtle features through its
hidden nodes. Already, there is evidence deep learning can
surpass the efficacy of classical methods [285], even using generic deep convolutional networks trained on natural images
[286], known as transfer learning. Recent work by Johnson
et al. [287] demonstrated how the use of a conditional adversarial autoencoder allows for a probabilistic interpretation of cell
and nuclear morphology and structure localization from fluorescence images. The proposed model is able to generalize well
to a wide range of subcellular localizations. The generative
nature of the model allows it to produce high-quality synthetic
images predicting localization of subcellular structures by
directly modelling the localization of fluorescent labels.
Notably, this approach reduces the modelling time by omitting
the subcellular structure segmentation step.
The impact of further improvements on biomedicine could
be enormous. Comparing cell population morphologies using
conventional methods of segmentation and feature extraction
has already proven useful for functionally annotating genes

3.12. Single-cell data
Single-cell methods are generating excitement as biologists
characterize the vast heterogeneity within unicellular species
and between cells of the same tissue type in the same organism
[291]. For instance, tumour cells and neurons can both harbour
extensive somatic variation [292]. Understanding single-cell
diversity in all its dimensions—genetic, epigenomic, transcriptomic, proteomic, morphologic and metabolic—is key if
treatments are to be targeted not only to a specific individual,
but also to specific pathological subsets of cells. Single-cell
methods also promise to uncover a wealth of new biological
knowledge. A sufficiently large population of single cells will
have enough representative ‘snapshots’ to recreate timelines
of dynamic biological processes. If tracking processes over
time is not the limiting factor, single-cell techniques can provide maximal resolution compared to averaging across all
cells in bulk tissue, enabling the study of transcriptional bursting with single-cell fluorescence in situ hybridization or the
heterogeneity of epigenomic patterns with single-cell Hi-C or
ATAC-seq [293,294]. Joint profiling of single-cell epigenomic
and transcriptional states provides unprecedented views of
regulatory processes [295].
However, large challenges exist in studying single cells.
Relatively few cells can be assayed at once using current droplet, imaging or microwell technologies, and low-abundance
molecules or modifications may not be detected by chance
due to a phenomenon known as dropout, not to be confused
with the dropout layer of deep learning. To solve this problem, Angermueller et al. [296] trained a neural network to
predict the presence or the absence of methylation of a
specific CpG site in single cells based on surrounding methylation signal and underlying DNA sequence, achieving
several percentage points of improvement compared to
random forests or deep networks trained only on CpG or
sequence information. Similar deep learning methods have
been applied to impute low-resolution ChIP-seq signal from
bulk tissue with great success, and they could easily be
adapted to single-cell data [193,297]. Deep learning has also
been useful for dealing with batch effects [298].
Examining populations of single cells can reveal biologically meaningful subsets of cells as well as their underlying
gene regulatory networks [299]. Unfortunately, machine learning methods generally struggle with imbalanced data—when
there are many more examples of class 1 than class 2—because
prediction accuracy is usually evaluated over the entire dataset.
To tackle this challenge, Arvaniti et al. [300] classified healthy
and cancer cells expressing 25 markers by using the most discriminative filters from a CNN trained on the data as a linear
classifier. They achieved impressive performance, even for
cell types where the subset percentage ranged from 0.1 to
1%, significantly outperforming logistic regression and
distance-based outlier detection methods. However, they did
not benchmark against random forests, which tend to work
better for imbalanced data, and their data were relatively
low dimensional.
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and alleles, identifying the cellular target of small molecules,
and identifying disease-specific phenotypes suitable for
drug screening [288–290]. Deep learning would bring to
these new kinds of experiments—known as image-based
profiling or morphological profiling—a higher degree of accuracy, stemming from the freedom from human-tuned feature
extraction strategies.
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classifier trained on the compressed features from the middle
layer of the autoencoder outperformed previous methods in
predicting protein function.
Hamilton et al. [280] addressed the issue of large, heterogeneous and changing networks with an inductive approach
called GraphSAGE. By finding node embeddings through
learned aggregator functions that describe the node and its
neighbours in the network, the GraphSAGE approach
allows for the generalization of the model to new graphs.
In a classification task for the prediction of protein function,
Chen & Zhu [281] optimized this approach and enhanced
the graph convolutional network with a preprocessing step
that uses an approximation to the dropout operation. This
preprocessing effectively reduces the number of graph convolutional layers and it significantly improves both training
time and prediction accuracy.
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Metagenomics, which refers to the study of genetic material—
16S rRNA or whole-genome shotgun DNA—from microbial
communities, has revolutionized the study of micro-scale ecosystems within and around us. In recent years, machine
learning has proved to be a powerful tool for metagenomic
analysis. 16S rRNA has long been used to deconvolve mixtures
of microbial genomes, yet this ignores more than 99% of the
genomic content. Subsequent tools aimed to classify 300–
3000 bp reads from complex mixtures of microbial genomes
based on tetranucleotide frequencies, which differ across
organisms [308], using supervised [309,310] or unsupervised
methods [311]. Then, researchers began to use techniques
that could estimate relative abundances from an entire
sample faster than classifying individual reads [312–315].
There is also great interest in identifying and annotating
sequence reads [316,317]. However, the focus on taxonomic
and functional annotation is just the first step. Several groups
have proposed methods to determine host or environment
phenotypes from the organisms that are identified [318–321]
or overall sequence composition [322]. Also, researchers have
looked into how feature selection can improve classification
[321,323], and techniques have been proposed that are classifierindependent [324,325].

3.14. Sequencing and variant calling
While we have so far primarily discussed the role of deep learning in analysing genomic data, deep learning can also
substantially improve our ability to obtain the genomic data
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Most neural networks are used for phylogenetic classification or functional annotation from sequence data where
there is ample data for training. Neural networks have been
applied successfully to gene annotation (e.g. Orphelia [326]
and FragGeneScan [327]). Representations (similar to Word2Vec [105] in NLP) for protein family classification have been
introduced and classified with a skip-gram neural network
[328]. RNNs show good performance for homology and
protein family identification [329,330].
One of the first techniques of de novo genome binning used
self-organizing maps, a type of neural network [311]. Essinger
et al. [331] used Adaptive Resonance Theory to cluster similar
genomic fragments and showed that it had better performance
than k-means. However, other methods based on interpolated
Markov models [332] have performed better than these early
genome binners. Neural networks can be slow and therefore have had limited use for reference-based taxonomic
classification, with TAC-ELM [333] being the only neural
network-based algorithm to taxonomically classify massive
amounts of metagenomic data. An initial study successfully
applied neural networks to taxonomic classification of 16S
rRNA genes, with convolutional networks providing about 10%
accuracy genus-level improvement over RNNs and random
forests [334]. However, this study evaluated only 3000 sequences.
Neural network uses for classifying phenotype from the
microbial composition are just beginning. A simple multilayer perceptron (MLP) was able to classify wound severity
from microbial species present in the wound [335]. Recently,
Ditzler et al. [336] associated soil samples with pH level using
MLPs, DBNs and RNNs. Besides classifying samples appropriately, internal phylogenetic tree nodes inferred by the
networks represented features for low and high pH. Thus,
hidden nodes might provide biological insight as well as
new features for future metagenomic sample comparison.
Also, an initial study has shown promise of these networks
for diagnosing disease [337].
Challenges remain in applying deep neural networks to
metagenomics problems. They are not yet ideal for phenotype
classification because most studies contain tens of samples and
hundreds or thousands of features (species). Such underdetermined, or ill-conditioned, problems are still a challenge for
deep neural networks that require many training examples.
Also, due to convergence issues [338], taxonomic classification
of reads from whole-genome sequencing seems out of reach at
the moment for deep neural networks. There are only thousands of full-sequenced genomes as compared to hundreds
of thousands of 16S rRNA sequences available for training.
However, because RNNs have been applied to base calls
for the Oxford Nanopore long-read sequencer with some success [339] (discussed below), one day the entire pipeline, from
denoising to functional classification, may be combined into
one step using powerful LSTMs [340]. For example, metagenomic assembly usually requires binning then assembly,
but could deep neural nets accomplish both tasks in one network? We believe the greatest potential for deep learning is to
learn the complete characteristics of a metagenomic sample in
one complex network.
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Neural networks can also learn low-dimensional representations of single-cell gene expression data for visualization,
clustering and other tasks. Both scvis [301] and scVI [302] are
unsupervised approaches based on VAEs. Whereas scvis primarily focuses on single-cell visualization as a replacement
for t-Distributed Stochastic Neighbour Embedding [303], the
scVI model accounts for zero-inflated expression distributions
and can impute zero values that are due to technical effects.
Beyond VAEs, Lin et al. [304] developed a supervised model
to predict cell type. Similar to transfer learning approaches
for microscopy images [286], they demonstrated that the
hidden layer representations were informative in general and
could be used to identify cellular subpopulations or match
new cells to known cell types. The supervised neural network’s
representation was better overall at retrieving cell types than
alternatives, but all methods struggled to recover certain cell
types such as haematopoietic stem cells and inner cell mass
cells. As the Human Cell Atlas [305] and related efforts generate more single-cell expression data, there will be opportunities
to assess how well these low-dimensional representations generalize to new cell types as well as abundant training data to
learn broadly applicable representations.
The sheer quantity of omic information that can be
obtained from each cell, as well as the number of cells in each
dataset, uniquely position single-cell data to benefit from
deep learning. In the future, lineage tracing could be revolutionized by using autoencoders to reduce the feature space of
transcriptomic or variant data followed by algorithms to
learn optimal cell differentiation trajectories [306] or by feeding
cell morphology and movement into neural networks [284].
Reinforcement learning algorithms [307] could be trained on
the evolutionary dynamics of cancer cells or bacterial cells
undergoing selection pressure and reveal whether patterns of
adaptation are random or deterministic, allowing us to develop
therapeutic strategies that forestall resistance. We are excited to
see the creative applications of deep learning to single-cell
biology that emerge over the next few years.
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3.15. Neuroscience
Artificial neural networks were originally conceived as a
model for computation in the brain [7]. Although deep
neural networks have evolved to become a workhorse
across many fields, there is still a strong connection between
deep networks and the study of the brain. The rich parallel
history of artificial neural networks in computer science
and neuroscience is reviewed in [346–348].
CNNs were originally conceived as faithful models of
visual information processing in the primate visual system,
and are still considered so [349]. The activations of hidden
units in consecutive layers of deep convolutional networks
have been found to parallel the activity of neurons in consecutive brain regions involved in processing visual scenes.
Such models of neural computation are called ‘encoding’
models, as they predict how the nervous system might
encode sensory information in the world.
Even when they are not directly modelling biological
neurons, deep networks have been a useful computational
tool in neuroscience. They have been developed as statistical
time-series models of neural activity in the brain. And in
contrast to the encoding models described earlier, these
models are used for decoding neural activity, for instance,
in brain –machine interfaces [350]. They have been crucial
to the field of connectomics, which is concerned with mapping the connectivity of biological neural networks in the
brain. In connectomics, deep networks are used to segment
the shapes of individual neurons and to infer their connectivity from 3D electron microscopic images [351], and they
have also been used to infer causal connectivity from optical
measurement and perturbation of neural activity [352].
It is an exciting time for neuroscience. Recent rapid progress in deep networks continues to inspire new machine
learning-based models of brain computation [346]. And
neuroscience continues to inspire new models of artificial
intelligence [348].

4. The impact of deep learning in treating
disease and developing new treatments
Given the need to make better, faster interventions at the
point of care—incorporating the complex calculus of a
patient’s symptoms, diagnostics and life history—there
have been many attempts to apply deep learning to patient
treatment. Success in this area could help to enable
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simulated mutations and spiked them into somatic and germline RNA-seq data, then trained and tested a neural network
on simulated paired RNA-seq and exome sequencing data
[345]. However, because this model was not subsequently
tested on ground-truth datasets, it is unclear whether simulation can produce sufficiently realistic data to produce
reliable models.
Method development for interpreting new types of
sequencing data has historically taken two steps: first,
easily implemented hard cutoffs that prioritize specificity
over sensitivity, then expert development of probabilistic
models with hand-developed inputs [345]. We anticipate
that these steps will be replaced by deep learning, which
will infer features simply by its ability to optimize a complex
model against data.
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itself. We discuss two specific challenges: calling SNPs and
indels (insertions and deletions) with high specificity and sensitivity and improving the accuracy of new types of data such
as nanopore sequencing. These two tasks are critical for studying rare variation, allele-specific transcription and translation,
and splice site mutations. In the clinical realm, sequencing of
rare tumour clones and other genetic diseases will require the
accurate calling of SNPs and indels.
Current methods achieve relatively high (greater than
99%) precision at 90% recall for SNPs and indel calls from
Illumina short-read data [341], yet this leaves a large
number of potentially clinically important remaining false
positives and false negatives. These methods have so far
relied on experts to build probabilistic models that reliably
separate signal from noise. However, this process is timeconsuming and fundamentally limited by how well we
understand and can model the factors that contribute to
noise. Recently, two groups have applied deep learning to
construct data-driven unbiased noise models. One of these
models, DeepVariant, leverages Inception, a neural network
trained for image classification by Google Brain, by encoding
reads around a candidate SNP as a 221  100 bitmap image,
where each column is a nucleotide and each row is a read
from the sample library [341]. The top five rows represent
the reference, and the bottom 95 rows represent randomly
sampled reads that overlap the candidate variant. Each
RGBA (red/green/blue/alpha) image pixel encodes the
base (A, C, G, T) as a different red value, quality score as a
green value, strand as a blue value and variation from the
reference as the alpha value. The neural network outputs
genotype probabilities for each candidate variant. They
were able to achieve better performance than GATK [342], a
leading genotype caller, even when GATK was given information about population variation for each candidate
variant. Another method, still in its infancy, hand-developed
62 features for each candidate variant and fed these vectors
into a fully connected deep neural network [343]. Unfortunately, this feature set required at least 15 iterations of
software development to fine-tune, which suggests that
these models may not generalize.
Variant calling will benefit more from optimizing neural
network architectures than from developing features by
hand. An interesting and informative next step would be to rigorously test if encoding raw sequence and quality data as an
image, tensor or some other mixed format produces the best
variant calls. Because many of the latest neural network architectures (ResNet, Inception, Xception and others) are already
optimized for and pre-trained on generic, large-scale image
datasets [344], encoding genomic data as images could prove
to be a generally effective and efficient strategy.
In limited experiments, DeepVariant was robust to
sequencing depth, read length and even species [341]. However, a model built on Illumina data, for instance, may not be
optimal for Pacific Biosciences long-read data or MinION
nanopore data, which have vastly different specificity
and sensitivity profiles and signal-to-noise characteristics.
Recently, Boža et al. [339] used bidirectional RNNs to infer
the E. coli sequence from MinION nanopore electric current
data with higher per-base accuracy than the proprietary
hidden Markov model-based algorithm Metrichor. Unfortunately, training any neural network requires a large amount
of data, which is often not available for new sequencing technologies. To circumvent this, one very preliminary study

In 1996, Tu [355] compared the effectiveness of artificial neural
networks and logistic regression, questioning whether these
techniques would replace traditional statistical methods for
predicting medical outcomes such as myocardial infarction
[356] or mortality [357]. He posited that while neural networks
have several advantages in representational power, the difficulties in interpretation may limit clinical applications, a
limitation that still remains today. In addition, the challenges
faced by physicians parallel those encountered by deep learning. For a given patient, the number of possible diseases is
very large, with a long tail of rare diseases and patients are
highly heterogeneous and may present with very different
signs and symptoms for the same disease. Still, in 2006
Lisboa & Taktak [358] examined the use of artificial neural networks in medical journals, concluding that they improved
healthcare relative to traditional screening methods in 21 of
27 studies. Recent applications of deep learning in pharmacogenomics and pharmacoepigenomics show the potential for
improving patient treatment response and outcome prediction
using patient-specific data, pharmacogenomic targets and
pharmacological knowledge bases [20].
While further progress has been made in using deep
learning for clinical decision-making, it is hindered by a challenge common to many deep learning applications: it is much
easier to predict an outcome than to suggest an action to
change the outcome. Several attempts [121,123] at recasting
the clinical decision-making problem into a prediction problem (i.e. prediction of which treatment will most improve
the patient’s health) have accurately predicted survival patterns, but technical and medical challenges remain for
clinical adoption (similar to those for categorization). In particular, remaining barriers include actionable interpretability
of deep learning models, fitting deep models to limited and
heterogeneous data, and integrating complex predictive
models into a dynamic clinical environment.
A critical challenge in providing treatment recommendations is identifying a causal relationship for each
recommendation. Causal inference is often framed in terms
of the counterfactual question [359]. Johansson et al. [360]
use deep neural networks to create representation models
for covariates that capture nonlinear effects and show significant performance improvements over existing models. In a
less formal approach, Kale et al. [361] first create a deep
neural network to model clinical time series and then analyse
the relationship of the hidden features to the output using a
causal approach.
A common challenge for deep learning is the interpretability of the models and their predictions. The task of
clinical decision-making is necessarily risk-averse, so model
interpretability is key. Without clear reasoning, it is difficult
to establish trust in a model. As described above, there has
been some work to directly assign treatment plans without
interpretability; however, the removal of human experts
from the decision-making loop make the models difficult to

4.1.1. Predicting patient trajectories
A common application for deep learning in this domain is
the temporal structure of healthcare records. Many studies
[362–365] have used RNNs to categorize patients, but most
stop short of suggesting clinical decisions. Nemati et al.
[366] used deep reinforcement learning to optimize a heparin
dosing policy for intensive care patients. However, because
the ideal dosing policy is unknown, the model’s predictions
must be evaluated on counterfactual data. This represents a
common challenge when bridging the gap between research
and clinical practice. Because the ground-truth is unknown,
researchers struggle to evaluate model predictions in the
absence of interventional data, but the clinical application is
unlikely until the model has been shown to be effective.
The impressive applications of deep reinforcement learning
to other domains [307] have relied on the knowledge of the
underlying processes (e.g. the rules of the game). Some
models have been developed for targeted medical problems
[367], but a generalized engine is beyond current capabilities.

4.1.2. Clinical trial efficiency
A clinical deep learning task that has been more successful is
the assignment of patients to clinical trials. Ithapu et al. [368]
used a randomized denoising autoencoder to learn a multimodal imaging marker that predicts future cognitive and
neural decline from positron emission tomography (PET),
amyloid florbetapir PET and structural magnetic resonance
imaging. By accurately predicting which cases will progress
to dementia, they were able to efficiently assign patients to a
clinical trial and reduced the required sample sizes by a
factor of five. Similarly, Artemov et al. [369] applied deep learning to predict which clinical trials were likely to fail and which
were likely to succeed. By predicting the side effects and pathway activations of each drug and translating these activations
to a success probability, their deep learning-based approach
was able to significantly outperform a random forest classifier
trained on gene expression changes. These approaches suggest
promising directions to improve the efficiency of clinical trials
and accelerate drug development.

4.2. Drug repositioning
Drug repositioning (or repurposing) is an attractive option for
delivering new drugs to the market because of the high costs
and failure rates associated with more traditional drug discovery approaches [370,371]. A decade ago, the Connectivity Map
[372] had a sizeable impact. Reverse matching disease gene
expression signatures with a large set of reference compound
profiles allowed researchers to formulate repurposing hypotheses at scale using a simple non-parametric test. Since then,
several advanced computational methods have been applied
to formulate and validate drug repositioning hypotheses
[373–375]. Using supervised learning and collaborative filtering to tackle this type of problem is proving successful,
especially when coupling disease or compound omic data
with topological information from protein–protein or
protein–compound interaction networks [376–378].
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4.1. Clinical decision-making

integrate with clinical practice. To alleviate this challenge,
several studies have attempted to create more interpretable
deep models, either specifically for healthcare or as a general
procedure for deep learning (see Discussion).
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personalized healthcare or precision medicine [353,354]. Earlier, we reviewed approaches for patient categorization. Here,
we examine the potential for better treatment, which broadly,
may be divided into methods for improved choices of
interventions for patients and those for development
of new interventions.
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4.3.1. Ligand-based prediction of bioactivity
High-throughput chemical screening in biomedical research
aims to improve therapeutic options over a long-term horizon
[22]. The objective is to discover which small molecules (also
referred to as chemical compounds or ligands) specifically
affect the activity of a target, such as a kinase, PPI or broader
cellular phenotype. This screening is often one of the first
steps in a long drug discovery pipeline, where novel molecules are pursued for their ability to inhibit or enhance
disease-relevant biological mechanisms [385]. Initial hits are
confirmed to eliminate false positives and proceed to the
lead generation stage [386], where they are evaluated for
absorption, distribution, metabolism, excretion and toxicity
(ADMET) and other properties. It is desirable to advance
multiple lead series, clusters of structurally similar active
chemicals, for further optimization by medicinal chemists to
protect against unexpected failures in the later stages of
drug discovery [385].
Computational work in this domain aims to identify sufficient candidate active compounds without exhaustively
screening libraries of hundreds of thousands or millions of
chemicals. Predicting chemical activity computationally is
known as virtual screening. An ideal algorithm will rank a
sufficient number of active compounds before the inactives,

4.3.2. Chemical featurization and representation learning
Much of the recent excitement in this domain has come from
what could be considered a creative experimentation phase,
in which deep learning has offered novel possibilities for
feature representation and modelling of chemical compounds. A molecular graph, where atoms are labelled
nodes and bonds are labelled edges, is a natural way to represent a chemical structure. Chemical features can be
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but the rankings of actives relative to other actives and inactives are less important [387]. Computational modelling also
has the potential to predict ADMET traits for lead generation
[388] and how drugs are metabolized [389].
Ligand-based approaches train on chemicals’ features without modelling target features (e.g. protein structure). Neural
networks have a long history in this domain [21,23], and the
2012 Merck Molecular Activity Challenge on Kaggle generated
substantial excitement about the potential for high-parameter
deep learning approaches. The winning submission was an
ensemble that included a multi-task MLP network [390]. The
sponsors noted drastic improvements over a random forest
baseline, remarking ‘we have seldom seen any method in the
past 10 years that could consistently outperform [random
forest] by such a margin’ [391], but not all outside experts
were convinced [392]. Subsequent work (reviewed in more
detail by Goh et al. [4]) explored the effects of jointly modelling
far more targets than the Merck challenge [393,394], with
Ramsundar et al. [394] showing that the benefits of multi-task
networks had not yet saturated even with 259 targets.
Although DeepTox [395], a deep learning approach, won
another competition, the Toxicology in the 21st Century
(Tox21) Data Challenge, it did not dominate alternative
methods as thoroughly as in other domains. DeepTox was
the top performer on nine of 15 targets and highly competitive
with the top performer on the others. However, for many targets, there was little separation between the top two or three
methods.
The nuanced Tox21 performance may be more reflective of
the practical challenges encountered in ligand-based chemical
screening than the extreme enthusiasm generated by the Merck
competition. A study of 22 ADMET tasks demonstrated that
there are limitations to multi-task transfer learning that are in
part a consequence of the degree to which tasks are related
[388]. Some of the ADMET datasets showed superior performance in multi-task models with only 22 ADMET tasks
compared to multi-task models with over 500 less-similar
tasks. In addition, the training datasets encountered in practical
applications may be tiny relative to what is available in public
datasets and organized competitions. A study of BACE-1
inhibitors included only 1547 compounds [396]. Machine
learning models were able to train on this limited dataset,
but overfitting was a challenge and the differences between
random forests and a deep neural network were negligible,
especially in the classification setting. Overfitting is still a problem in larger chemical screening datasets with tens or
hundreds of thousands of compounds because the number of
active compounds can be very small, of the order of 0.1%
of all tested chemicals for a typical target [397]. This has
motivated low-parameter neural networks that emphasize
compound–compound similarity, such as influence-relevance
voter [387,398], instead of predicting compound activity
directly from chemical features.
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For example, Menden et al. [379] used a shallow neural
network to predict sensitivity of cancer cell lines to drug
treatment using both cell line and drug features, opening
the door to precision medicine and drug repositioning opportunities in cancer. More recently, Aliper et al. [37] used geneand pathway-level drug perturbation transcriptional profiles
from the Library of Network-Based Cellular Signatures [380]
to train a fully connected deep neural network to predict
drug therapeutic uses and indications. By using confusion
matrices and leveraging misclassification, the authors
formulated a number of interesting hypotheses, including
repurposing cardiovascular drugs such as otenzepad and
pinacidil for neurological disorders.
Drug repositioning can also be approached by attempting
to predict novel drug–target interactions and then repurposing
the drug for the associated indication [381,382]. Wang et al.
[383] devised a pairwise input neural network with two
hidden layers that takes two inputs, a drug and a target binding
site, and predicts whether they interact. Wang et al. [38] trained
individual RBMs for each target in a drug–target interaction
network and used these models to predict novel interactions
pointing to new indications for existing drugs. Wen et al. [39]
extended this concept to deep learning by creating a DBN
called DeepDTIs, which predicts interactions using chemical
structure and protein sequence features.
Drug repositioning appears an obvious candidate for deep
learning both because of the large amount of high-dimensional
data available and the complexity of the question being asked.
However, perhaps the most promising piece of work in this
space [37] is more of a proof of concept than a real-world
hypothesis-generation tool; notably, deep learning was used
to predict drug indications but not for the actual repositioning.
At present, some of the most popular state-of-the-art methods
for signature-based drug repurposing [384] do not use predictive modelling. A mature and production-ready framework for
drug repositioning via deep learning is currently missing.

4.3.3. Structure-based prediction of bioactivity
When protein structure is available, virtual screening has traditionally relied on docking programs to predict how a
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worse. The authors also demonstrate the limitations of transfer learning as embeddings learned from the Tox21 assays
have little utility for a drug adverse reaction dataset.
These novel learned chemical feature representations may
prove to be essential for accurately predicting why some compounds with similar structures yield similar target effects and
others produce drastically different results. Currently, these
methods are enticing but do not necessarily outperform classic approaches by a large margin. The neural fingerprints
[403] were narrowly beaten by regression using traditional
circular fingerprints on a drug efficacy prediction task but
were superior for predicting solubility or photovoltaic efficiency. In the original study, graph convolutions [405]
performed comparably to a multi-task network using standard fingerprints and slightly better than the neural
fingerprints [403] on the drug efficacy task but were slightly
worse than the influence-relevance voter method on an HIV
dataset [387]. Broader recent benchmarking has shown that
relative merits of these methods depend on the dataset and
cross-validation strategy [410], though evaluation in this
domain often uses the area under the receiver operating
characteristic curve (AUROC) [411], which has limited utility
due to the large class imbalance (see Discussion).
We remain optimistic about the potential of deep learning
and specifically representation learning in drug discovery. Rigorous benchmarking on broad and diverse prediction tasks
will be as important as novel neural network architectures to
advance the state of the art and convincingly demonstrate
superiority over traditional cheminformatics techniques. Fortunately, there has recently been much progress in this direction.
The DeepChem software [406,412] and MoleculeNet benchmarking suite [410] built upon it contain chemical bioactivity
and toxicity prediction datasets, multiple compound featurization approaches including graph convolutions, and various
machine learning algorithms ranging from standard baselines
like logistic regression and random forests to recent neural network architectures. Independent research groups have already
contributed additional datasets and prediction algorithms to
DeepChem. Adoption of common benchmarking evaluation
metrics, datasets and baseline algorithms has the potential to
establish the practical utility of deep learning in chemical bioactivity prediction and lower the barrier to entry for machine
learning researchers without biochemistry expertise.
One open question in ligand-based screening pertains to
the benefits and limitations of transfer learning. Multi-task
neural networks have shown the advantages of jointly modelling many targets [393,394]. Other studies have shown the
limitations of transfer learning when the prediction tasks
are insufficiently related [388,406]. This has important implications for representation learning. The typical approach to
improve deep learning models by expanding the dataset
size may not be applicable if only ‘related’ tasks are
beneficial, especially because task–task relatedness is illdefined. The massive chemical state space will also influence
the development of unsupervised representation learning
methods [401,413]. Future work will establish whether it is
better to train on massive collections of diverse compounds,
drug-like small molecules or specialized subsets.
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represented as a list of molecular descriptors such as
molecular weight, atom counts, functional groups, charge
representations, summaries of atom– atom relationships in
the molecular graph, and more sophisticated derived properties [399]. Traditional machine learning approaches relied on
preprocessing the graph into a feature vector of molecular
descriptors or a fixed-width bit vector known as a fingerprint
[400]. The same fingerprints have been used by some drug –
target interaction methods discussed above [39]. An overly
simplistic but approximately correct view of chemical fingerprints is that each bit represents the presence or the absence
of a particular chemical substructure in the molecular
graph. Instead of using molecular descriptors or fingerprints
as input, modern neural networks can represent chemicals as
textual strings [401] or images [402] or operate directly on the
molecular graph, which has enabled strategies for learning
novel chemical representations.
Virtual screening and chemical property prediction have
emerged as one of the major applications areas for graphbased neural networks. Duvenaud et al. [403] generalized standard circular fingerprints by substituting discrete operations in
the fingerprinting algorithm with operations in a neural network, producing a real-valued feature vector instead of a bit
vector. Other approaches offer trainable networks that can
learn chemical feature representations that are optimized for
a particular prediction task. Lusci et al. [404] applied recursive
neural networks for directed acyclic graphs to undirected molecular graphs by creating an ensemble of directed graphs in
which one atom is selected as the root node. Graph convolutions on undirected molecular graphs have eliminated the
need to enumerate artificially directed graphs, learning feature
vectors for atoms that are a function of the properties of neighbouring atoms and local regions on the molecular graph [405–
407]. More sophisticated graph algorithms [408,409] addressed
limitations of standard graph convolutions that primarily operate on each node’s local neighbourhood. We anticipate that
these graph-based neural networks could also be applicable
in other types of biological networks, such as the PPI networks
we discussed previously.
Advances in chemical representation learning have also
enabled new strategies for learning chemical–chemical similarity functions. Altae-Tran et al. [406] developed a one-shot
learning network to address the reality that most practical
chemical screening studies are unable to provide the thousands or millions of training compounds that are needed to
train larger multi-task networks. Using graph convolutions
to featurize chemicals, the network learns an embedding
from compounds into a continuous feature space such that
compounds with similar activities in a set of training tasks
have similar embeddings. The approach is evaluated in an
extremely challenging setting. The embedding is learned
from a subset of prediction tasks (e.g. activity assays for individual proteins), and only one to 10 labelled examples are
provided as training data on a new task. On Tox21 targets,
even when trained with one task-specific active compound
and one inactive compound, the model is able to generalize
reasonably well because it has learned an informative embedding function from the related tasks. Random forests, which
cannot take advantage of the related training tasks, trained
in the same setting are only slightly better than a random
classifier. Despite the success on Tox21, performance on
MUV datasets, which contains assays designed to be challenging for chemical informatics algorithms, is considerably
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De novo drug design attempts to model the typical design–
synthesize–test cycle of drug discovery [420,421]. It explores
an estimated 1060 synthesizable organic molecules with druglike properties without explicit enumeration [397]. To test or
score structures, algorithms like those discussed earlier are
used. To ‘design’ and ‘synthesize’, traditional de novo design
software relied on classical optimizers such as genetic
algorithms. Unfortunately, this often leads to overfit, ‘weird’
molecules, which are difficult to synthesize in the laboratory.
Current programs have settled on rule-based virtual chemical
reactions to generate molecular structures [421]. Deep learning
models that generate realistic, synthesizable molecules have
been proposed as an alternative. In contrast to the classical,
symbolic approaches, generative models learned from data
would not depend on laboriously encoded expert knowledge.
The challenge of generating molecules has parallels to the generation of syntactically and semantically correct text [422].
As deep learning models that directly output (molecular)
graphs remain under-explored, generative neural networks
for drug design typically represent chemicals with the

5. Discussion
Despite the disparate types of data and scientific goals in the
learning tasks covered above, several challenges are broadly
important for deep learning in the biomedical domain.
Here, we examine these factors that may impede further progress, ask what steps have already been taken to overcome
them, and suggest future research directions.

5.1. Customizing deep learning models reflects a
trade-off between bias and variance
Some of the challenges in applying deep learning are shared
with other machine learning methods. In particular, many
problem-specific optimizations described in this review reflect
a recurring universal trade-off—controlling the flexibility of a
model in order to maximize predictivity. Methods for adjusting
the flexibility of deep learning models include dropout,
reduced data projections and transfer learning (described
below). One way of understanding such model optimizations
is that they incorporate external information to limit model
flexibility and thereby improve predictions. This balance is formally described as a trade-off between ‘bias and variance’ [11].
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simplified molecular-input line-entry system (SMILES), a standard string-based representation with characters that represent
atoms, bonds and rings [423]. This allows molecules to be treated as sequences and leveraging recent progress in RNNs.
Gómez-Bombarelli et al. [401] designed a SMILES-to-SMILES
autoencoder to learn a continuous latent feature space for
chemicals. In this learned continuous space, it was possible to
interpolate between continuous representations of chemicals
in a manner that is not possible with discrete (e.g. bit vector
or string) features or in symbolic, molecular graph space.
Even more interesting is the prospect of performing gradientbased or Bayesian optimization of molecules within this latent
space. The strategy of constructing simple, continuous features
before applying supervised learning techniques is reminiscent
of autoencoders trained on high-dimensional EHR data [115].
A drawback of the SMILES-to-SMILES autoencoder is that
not all SMILES strings produced by the autoencoder’s decoder
correspond to valid chemical structures. Recently, the Grammar
Variational Autoencoder, which takes the SMILES grammar
into account and is guaranteed to produce syntactically valid
SMILES, has been proposed to alleviate this issue [424].
Another approach to de novo design is to train characterbased RNNs on large collections of molecules, for example,
ChEMBL [425], to first obtain a generic generative model for
drug-like compounds [423]. These generative models successfully learn the grammar of compound representations,
with 94% [426] or nearly 98% [423] of generated SMILES corresponding to valid molecular structures. The initial RNN is then
fine-tuned to generate molecules that are likely to be active
against a specific target by either continuing training on a
small set of positive examples [423] or adopting reinforcement learning strategies [426,427]. Both the fine-tuning and
reinforcement learning approaches can rediscover known,
held-out active molecules. The great flexibility of neural networks, and progress in generative models offers many
opportunities for deep architectures in de novo design
(e.g. the adaptation of GANs for molecules).
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compound best fits in the target’s binding site and score the
predicted ligand –target complex [414]. Recently, deep learning approaches have been developed to model protein
structure, which is expected to improve upon the simpler
drug –target interaction algorithms described above that represent proteins with feature vectors derived from amino acid
sequences [39,383].
Structure-based deep learning methods differ in whether
they use experimentally derived or predicted ligand –target
complexes and how they represent the 3D structure. The
Atomic CNN [415] and TopologyNet [416] models take 3D
structures from PDBBind [417] as input, ensuring the
ligand –target complexes are reliable. AtomNet [36] samples
multiple ligand poses within the target binding site, and
DeepVS [418] and Ragoza et al. [419] use a docking program
to generate protein –compound complexes. If they are sufficiently accurate, these latter approaches would have wider
applicability to a much larger set of compounds and proteins.
However, incorrect ligand poses will be misleading during
training, and the predictive performance is sensitive to the
docking quality [418].
There are two established options for representing a
protein–compound complex. One option, a 3D grid, can featurize the input complex [36,419]. Each entry in the grid
tracks the types of protein and ligand atoms in that region of
the 3D space or descriptors derived from those atoms. Alternatively, DeepVS [418] and atomic convolutions [415] offer
greater flexibility in their convolutions by eschewing the 3D
grid. Instead, they each implement techniques for executing
convolutions over atoms’ neighbouring atoms in the 3D
space. Gomes et al. [415] demonstrate that currently random
forest on a one-dimensional feature vector that describes the
3D ligand–target structure generally outperforms neural networks on the same feature vector as well as atomic
convolutions and ligand-based neural networks when predicting the continuous-valued inhibition constant on the PDBBind
refined dataset. However, in the long-term, atomic convolutions may ultimately overtake grid-based methods, as they
provide greater freedom to model atom–atom interactions
and the forces that govern binding affinity.

Making predictions in the presence of high-class imbalance
and differences between training and generalization data
are a common feature of many large biomedical datasets,
including deep learning models of genomic features, patient
classification, disease detection and virtual screening. Prediction of TF binding sites exemplifies the difficulties with
learning from highly imbalanced data. The human genome
has three billion base pairs, and only a small fraction of
them are implicated in specific biochemical activities. Less
than 1% of the genome can be confidently labelled as
bound for most TFs.
Estimating the false discovery rate (FDR) is a standard
method of evaluation in genomics that can also be applied
to deep learning model predictions of genomic features.
Using deep learning predictions for targeted validation
experiments of specific biochemical activities necessitates a
more stringent FDR (typically 5–25%). However, when predicted biochemical activities are used as features in other
models, such as gene expression models, a low FDR may
not be necessary.
What is the correspondence between FDR metrics and commonly used classification metrics such as AUPR and AUROC?
AUPR evaluates the average precision, or equivalently, the
average FDR across all recall thresholds. This metric provides
an overall estimate of performance across all possible use
cases, which can be misleading for targeted validation experiments. For example, classification of TF binding sites can
exhibit a recall of 0% at 10% FDR and AUPR greater than 0.6.
In this case, the AUPR may be competitive, but the predictions
are ill-suited for targeted validation that can only examine a
few of the highest-confidence predictions. Likewise, AUROC
evaluates the average recall across all false positive rate (FPR)
thresholds, which is often a highly misleading metric in
class-imbalanced domains [72,430]. Consider a classification
model with the recall of 0% at FDR less than 25% and 100%
recall at FDR greater than 25%. In the context of TF binding
predictions where only 1% of genomic regions are bound by
the TF, this is equivalent to a recall of 100% for FPR greater
than 0.33%. In other words, the AUROC would be 0.9967,
but the classifier would be useless for targeted validation. It
is not unusual to obtain a chromosome-wide AUROC greater
than 0.99 for TF binding predictions but a recall of 0% at 10%
FDR. Consequently, practitioners must select the metric most
tailored to their subsequent use case to use these methods
most effectively.

5.1.2. Formulation of classification labels
Genome-wide continuous signals are commonly formulated
into classification labels through signal peak detection. ChIPseq peaks are used to identify locations of TF binding and histone modifications. Such procedures rely on thresholding
criteria to define what constitutes a peak in the signal. This
inevitably results in a set of signal peaks that are close to the

5.1.3. Formulation of a performance upper bound
In assessing the upper bound on the predictive performance
of a deep learning model, it is necessary to incorporate
inherent between-study variation inherent to biomedical
research [431]. Study-level variability limits classification performance and can lead to underestimating prediction error if
the generalization error is estimated by splitting a single dataset. Analyses can incorporate data from multiple laboratories
and experiments to capture between-study variation within
the prediction model mitigating some of these issues.

5.2. Uncertainty quantification
Deep learning-based solutions for biomedical applications
could substantially benefit from guarantees on the reliability
of predictions and a quantification of uncertainty. Owing to
biological variability and precision limits of equipment, biomedical data do not consist of precise measurements but of
estimates with noise. Hence, it is crucial to obtain uncertainty
measures that capture how noise in input values propagates
through deep neural networks. Such measures can be used
for reliability assessment of automated decisions in clinical
and public health applications, and for guarding against
model vulnerabilities in the face of rare or adversarial
cases [432]. Moreover, in fundamental biological research,
measures of uncertainty help researchers distinguish between
true regularities in the data and patterns that are false or
merely anecdotal. There are two main uncertainties that one
can calculate: epistemic and aleatoric [433]. Epistemic uncertainty describes uncertainty about the model, its structure or
its parameters. This uncertainty is caused by insufficient
training data or by a difference in the training set and testing
set distributions, so it vanishes in the limit of infinite data.
On the other hand, aleatoric uncertainty describes uncertainty inherent in the observations. This uncertainty is due
to noisy or missing data, so it vanishes with the ability to
observe all independent variables with infinite precision.
A good way to represent aleatoric uncertainty is to design
an appropriate loss function with an uncertainty variable.
In the case of data-dependent aleatoric uncertainty, one
can train the model to increase its uncertainty when it is
incorrect due to noisy or missing data, and in the case of
task-dependent aleatoric uncertainty, one can optimize for
the best uncertainty parameter for each task [434]. Meanwhile, there are various methods for modelling epistemic
uncertainty, outlined below.
In classification tasks, confidence calibration is the problem
of using classifier scores to predict class membership probabilities that match the true membership likelihoods. These
membership probabilities can be used to assess the uncertainty
associated with assigning the example to each of the classes.
Guo et al. [435] observed that contemporary neural networks
are poorly calibrated and provided a simple recommendation
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5.1.1. Evaluation metrics for imbalanced classification

threshold, not sufficient to constitute a positive label but too
similar to positively labelled examples to constitute a negative
label. To avoid an arbitrary label for these examples, they may
be labelled as ‘ambiguous’. Ambiguously labelled examples
can then be ignored during model training and evaluation of
recall and FDR. The correlation between model predictions
on these examples and their signal values can be used to evaluate if the model correctly ranks these examples between
positive and negative examples.
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Although the bias-variance trade-off is common to all
machine learning applications, recent empirical and theoretical observations suggest that deep learning models may have
uniquely advantageous generalization properties [428,429].
Nevertheless, additional advances will be needed to establish
a coherent theoretical foundation that enables practitioners to
better reason about their models from first principles.
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5.3. Interpretation
As deep learning models achieve state-of-the-art performance in
a variety of domains, there is a growing need to make the
models more interpretable. Interpretability matters for two
main reasons. First, a model that achieves breakthrough performance may have identified patterns in the data that
practitioners in the field would like to understand. However,
this would not be possible if the model is a black box. Second,
interpretability is important for trust. If a model is making medical diagnoses, it is important to ensure the model is making
decisions for reliable reasons and is not focusing on an artefact
of the data. A motivating example of this can be found in
Ba & Caruana [448], where a model trained to predict the likelihood of death from pneumonia assigned lower risk to patients
with asthma, but only because such patients were treated as a
higher priority by the hospital. In the context of deep learning,
understanding the basis of a model’s output is particularly
important as deep learning models are unusually susceptible
to adversarial examples [449] and can output confidence
scores over 99.99% for samples that resemble pure noise.
As the concept of interpretability is quite broad, many
methods described as improving the interpretability of deep
learning models take disparate and often complementary
approaches.

5.3.1. Assigning example-specific importance scores
Several approaches ascribe importance on an examplespecific basis to the parts of the input that are responsible
for a particular output. These can be broadly divided into
perturbation- and backpropagation-based approaches.
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another framework for approximate Bayesian inference in
deep learning, where an invertible generative hypernetwork
maps isotropic Gaussian noise to parameters of the primary
network allowing for computationally cheap sampling and
efficient estimation of the posterior. Meanwhile, Lakshminarayanan et al. [446] proposed using deep ensembles, which are
traditionally used for boosting predictive performance, on
standard (non-Bayesian) neural networks to obtain wellcalibrated uncertainty estimates that are comparable to those
obtained by Bayesian neural networks. In cases where model
uncertainty is known to be caused by a difference in training
and testing distributions, domain adaptation-based techniques
can help mitigate the problem [220].
Despite the success and popularity of deep learning, some
deep learning models can be surprisingly brittle. Researchers
are actively working on modifications to deep learning frameworks to enable them to handle probability and embrace
uncertainty. Most notably, Bayesian modelling and deep learning are being integrated with renewed enthusiasm. As a result,
several opportunities for innovation arise: understanding the
causes of model uncertainty can lead to novel optimization
and regularization techniques, assessing the utility of uncertainty estimation techniques on various model architectures
and structures can be very useful to practitioners, and extending Bayesian deep learning to unsupervised settings can be a
significant breakthrough [447]. Unfortunately, uncertainty
quantification techniques are underused in the computational
biology communities and largely ignored in the current deep
learning for biomedicine literature. Thus, the practical value
of uncertainty quantification in biomedical domains is yet to
be appreciated.
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for calibration: temperature scaling, a single parameter special
case of Platt scaling [436]. In addition to confidence calibration, there is early work from Chryssolouris et al. [437] that
described a method for obtaining confidence intervals with
the assumption of normally distributed error for the neural network. More recently, Hendrycks & Gimpel [438] discovered
that incorrect or out-of-distribution examples usually have
lower maximum softmax probabilities than correctly classified
examples, allowing for effective detection of misclassified
examples. Liang et al. [439] used temperature scaling and
small perturbations to further separate the softmax scores of
correctly classified examples and the scores of out-ofdistribution examples, allowing for more effective detection.
This approach outperformed the baseline approaches by a
large margin, establishing a new state-of-the-art performance.
An alternative approach for obtaining principled uncertainty estimates from deep learning models is to use Bayesian
neural networks. Deep learning models are usually trained to
obtain the most likely parameters given the data. However,
choosing the single most likely set of parameters ignores the
uncertainty about which set of parameters (among the possible
models that explain the given dataset) should be used.
This sometimes leads to uncertainty in predictions when the
chosen likely parameters produce high-confidence but
incorrect results. On the other hand, the parameters of Bayesian
neural networks are modelled as full probability distributions.
This Bayesian approach comes with a whole host of benefits,
including better calibrated confidence estimates [440] and
more robustness to adversarial and out-of-distribution
examples [441]. Unfortunately, modelling the full posterior distribution for the model’s parameters given the data is usually
computationally intractable. One popular method for circumventing this high computational cost is called test-time
dropout [442], where an approximate posterior distribution is
obtained using variational inference. Gal & Ghahramani
[442] showed that a stack of fully connected layers with dropout between the layers is equivalent to approximate inference
in a Gaussian process model. The authors interpret dropout
as a variational inference method and apply their method to
CNNs. This is simple to implement and preserves the possibility of obtaining cheap samples from the approximate
posterior distribution. Operationally, obtaining model uncertainty for a given case becomes as straightforward as leaving
dropout turned on and predicting multiple times. The spread
of the different predictions is a reasonable proxy for model
uncertainty. This technique has been successfully applied in
an automated system for detecting diabetic retinopathy [443],
where uncertainty-informed referrals improved diagnostic
performance and allowed the model to meet the National
Health Service recommended levels of sensitivity and
specificity. The authors also found that entropy performs comparably to the spread obtained via test-time dropout for
identifying uncertain cases, and therefore it can be used instead
for automated referrals.
Several other techniques have been proposed for effectively
estimating predictive uncertainty as uncertainty quantification
for neural networks continues to be an active research area.
Recently, McClure & Kriegeskorte [444] observed that testtime sampling improved calibration of the probabilistic
predictions, sampling weights led to more robust uncertainty
estimates than sampling units, and spike-and-slab sampling
was superior to Gaussian dropconnect and Bernoulli dropout.
Krueger et al. [445] introduced Bayesian hypernetworks as

Another approach to understanding the network’s predictions
is to find artificial inputs that produce similar hidden representations to a chosen example. This can elucidate the features that
the network uses for prediction and drop the features that the
network is insensitive to. In the context of natural images,
Mahendran & Vedaldi [463] introduced the ‘inversion’ visualization, which uses gradient descent and backpropagation to
reconstruct the input from its hidden representation. The
method required placing a prior on the input to favour results
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5.3.3. Activation maximization
Activation maximization can reveal patterns detected by an
individual neuron in the network by generating images
which maximally activate that neuron, subject to some regularizing constraints. This technique was first introduced in Ehran
et al. [467] and applied in subsequent work [454,465,466,468].
Lanchantin et al. [206] applied class-based activation maximization to genomic sequence data. One drawback of this
approach is that neural networks often learn highly distributed
representations where several neurons cooperatively describe
a pattern of interest. Thus, visualizing patterns learned by
individual neurons may not always be informative.

5.3.4. RNN-specific approaches
Several interpretation methods are specifically tailored to
recurrent neural network architectures. The most common
form of interpretability provided by RNNs is through attention
mechanisms, which have been used in diverse problems such
as image captioning and machine translation to select portions
of the input to focus on generating a particular output
[469,470]. Deming et al. [471] applied the attention mechanism
to models trained on genomic sequence. Attention mechanisms provide insight into the model’s decision-making
process by revealing which portions of the input are used by
different outputs. Singh et al. [185] used a hierarchy of attention
layers to locate important genome positions and signals for
predicting gene expression from histone modifications. In the
clinical domain, Choi et al. [472] leveraged attention mechanisms to highlight which aspects of a patient’s medical history
were most relevant for making diagnoses. Choi et al. [473]
later extended this work to take into account the structure of
disease ontologies and found that the concepts represented
by the model aligned with medical knowledge. Note that
interpretation strategies that rely on an attention mechanism
do not provide insight into the logic used by the attention layer.
Visualizing the activation patterns of the hidden state of a
recurrent neural network can also be instructive. Early work
by Ghosh & Karamcheti [474] used cluster analysis to study
hidden states of comparatively small networks trained to
recognize strings from a finite-state machine. More recently,
Karpathy et al. [475] showed the existence of individual
cells in LSTMs that kept track of quotes and brackets in
character-level language models. To facilitate such analyses,
LSTMVis [476] allows interactive exploration of the hidden
state of LSTMs on different inputs.
Another strategy, adopted by Lanchatin et al. [206] looks
at how the output of a recurrent neural network changes as
longer and longer subsequences are supplied as input to
the network, where the subsequences begin with just the
first position and end with the entire sequence. In a binary
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5.3.2. Matching or exaggerating the hidden representation

that resemble natural images. For genomic sequence,
Finnegan & Song [464] used a Markov chain Monte Carlo algorithm to find the maximum-entropy distribution of inputs that
produced a similar hidden representation to the chosen input.
A related idea is ‘caricaturization’, where an initial image
is altered to exaggerate patterns that the network searches for
[465]. This is done by maximizing the response of neurons
that are active in the network, subject to some regularizing
constraints. Mordvintsev et al. [466] leveraged caricaturization to generate aesthetically pleasing images using neural
networks.
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Perturbation-based approaches change parts of the input
and observe the impact on the output of the network.
Alipanahi et al. [203] and Zhou & Troyanskaya [211] scored
genomic sequences by introducing virtual mutations at individual positions in the sequence and quantifying the change
in the output. Umarov et al. [224] used a similar strategy, but
with sliding windows where the sequence within each sliding
window was substituted with a random sequence. Kelley
et al. [229] inserted known protein-binding motifs into the
centres of sequences and assessed the change in predicted
accessibility. Ribeiro et al. [450] introduced LIME, which
constructs a linear model to locally approximate the output
of the network on perturbed versions of the input and assigns
importance scores accordingly. For analysing images,
Zeiler & Fergus [451] applied constant-value masks to different input patches. More recently, marginalizing over the
plausible values of an input has been suggested as a way to
more accurately estimate contributions [452].
A common drawback to perturbation-based approaches is
computational efficiency: each perturbed version of an input
requires a separate forward propagation through the network
to compute the output. As noted by Shrikumar et al. [221],
such methods may also underestimate the impact of features
that have saturated their contribution to the output, as can
happen when multiple redundant features are present. To
reduce the computational overhead of perturbation-based
approaches, Fong & Vedaldi [453] solve an optimization
problem using gradient descent to discover a minimal
subset of inputs to perturb in order to decrease the predicted
probability of a selected class. Their method converges in
many fewer iterations but requires the perturbation to have
a differentiable form.
Backpropagation-based methods, in which the signal from
a target output neuron is propagated backwards to the input
layer, are another way to interpret deep networks that sidestep
inefficiencies of the perturbation-based methods. A classic
example of this is calculating the gradients of the output with
respect to the input [454] to compute a ‘saliency map’. Bach
et al. [455] proposed a strategy called Layerwise Relevance
Propagation, which was shown to be equivalent to the
element-wise product of the gradient and input [221,456]. Networks with Rectified Linear Units create nonlinearities that
must be addressed. Several variants exist for handling this
[451,457]. Backpropagation-based methods are a highly active
area of research. Researchers are still actively identifying weaknesses [458], and new methods are being developed to address
them [221,459,460]. Lundberg & Lee [461] noted that several
importance scoring methods including integrated gradients
and LIME could all be considered approximations to Shapely
values [462], which have a long history in game theory for
assigning contributions to players in cooperative games.
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Interpretation of embedded or latent space features learned
through generative unsupervised models can reveal underlying
patterns otherwise masked in the original input. Embedded feature interpretation has been emphasized mostly in image- and
text-based applications [105,478], but applications to genomic
and biomedical domains are increasing.
For example, Way & Greene trained a VAE on gene
expression from The Cancer Genome Atlas (TCGA) [479]
and use latent space arithmetic to rapidly isolate and interpret gene expression features descriptive of high-grade
serous ovarian cancer subtypes [480]. The most differentiating VAE features were representative of biological processes
that are known to distinguish the subtypes. Latent space
arithmetic with features derived using other compression
algorithms were not as informative in this context [481].
Embedding discrete chemical structures with autoencoders
and interpreting the learned continuous representations
with latent space arithmetic has also facilitated predicting
drug-like compounds [401]. Furthermore, embedding biomedical text into lower dimensional latent spaces have improved
name entity recognition in a variety of tasks including
annotating clinical abbreviations, genes, cell lines and drug
names [78–81].
Other approaches have used interpolation through latent
space embeddings learned by GANs to interpret unobserved
intermediate states. For example, Osokin et al. [482] trained
GANs on two-channel fluorescent microscopy images to
interpret intermediate states of protein localization in yeast
cells. Goldsborough et al. [483] trained a GAN on fluorescent
microscopy images and used latent space interpolation and
arithmetic to reveal underlying responses to small molecule
perturbations in cell lines.

5.3.6. Miscellaneous approaches
It can often be informative to understand how the training
data affects model learning. Towards this end, Koh & Liang
[484] used influence functions, a technique from robust statistics, to trace a model’s predictions back through the
learning algorithm to identify the datapoints in the training
set that had the most impact on a given prediction. A more
free-form approach to interpretability is to visualize the activation patterns of the network on individual inputs and on
subsets of the data. ActiVis and CNNvis [485,486] are two
frameworks that enable interactive visualization and exploration of large-scale deep learning models. An orthogonal

5.3.7. Future outlook
While deep learning lags behind most Bayesian models in
terms of interpretability, the interpretability of deep learning
is comparable to or exceeds that of many other widely used
machine learning methods such as random forests or SVMs.
While it is possible to obtain importance scores for different
inputs in a random forest, the same is true for deep learning.
Similarly, SVMs trained with a nonlinear kernel are not easily
interpretable because the use of the kernel means that one
does not obtain an explicit weight matrix. Finally, it is
worth noting that some simple machine learning methods
are less interpretable in practice than one might expect.
A linear model trained on heavily engineered features
might be difficult to interpret as the input features themselves
are difficult to interpret. Similarly, a decision tree with many
nodes and branches may also be difficult for a human to
make sense of.
There are several directions that might benefit the development of interpretability techniques. The first is the
introduction of gold standard benchmarks that different
interpretability approaches could be compared against, similar in spirit to how the ImageNet [46] and CIFAR [489]
datasets spurred the development of deep learning for computer vision. It would also be helpful if the community
placed more emphasis on domains outside of computer
vision. Computer vision is often used as the example application of interpretability methods, but it is not the domain
with the most pressing need. Finally, closer integration of
interpretability approaches with popular deep learning frameworks would make it easier for practitioners to apply
and experiment with different approaches to understanding
their deep learning models.

5.4. Data limitations
A lack of large-scale, high-quality, correctly labelled training
data have impacted deep learning in nearly all applications
we have discussed. The challenges of training complex, highparameter neural networks from few examples are obvious,
but uncertainty in the labels of those examples can be just as
problematic. In genomics, labelled data may be derived from
an experimental assay with known and unknown technical
artefacts, biases and error profiles. It is possible to weight
training examples or construct Bayesian models to account
for uncertainty or non-independence in the data, as described
in the TF binding example above. As another example,
Park et al. [490] estimated shared non-biological signal between datasets to correct for non-independence related to
assay platform or other factors in a Bayesian integration of
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5.3.5. Latent space manipulation

strategy is to use a knowledge distillation approach to replace
a deep learning model with a more interpretable model that
achieves comparable performance. Towards this end, Che
et al. [487] used gradient boosted trees to learn interpretable
healthcare features from trained deep models.
Finally, it is sometimes possible to train the model to provide justifications for its predictions. Lei et al. [488] used a
generator to identify ‘rationales’, which are short and coherent pieces of the input text that produce similar results to
the whole input when passed through an encoder. The
authors applied their approach to a sentiment analysis task
and obtained substantially superior results compared to an
attention-based method.
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classification task, this can identify those positions that are
responsible for flipping the output of the network from negative to positive. If the RNN is bidirectional, the same process
can be repeated in the reverse sequence. As noted by the
authors, this approach was less effective at identifying motifs
compared with the gradient-based backpropagation approach
of Simonyan et al. [454], illustrating the need for more
sophisticated strategies to assign importance scores in RNNs.
Murdoch & Szlam [477] showed that the output of an
LSTM can be decomposed into a product of factors, where
each factor can be interpreted as the contribution at a particular time step. The contribution scores were then used to
identify key phrases from a model trained for sentiment
analysis and obtained superior results compared to scores
derived via a gradient-based approach.

5.5. Hardware limitations and scaling
Efficiently scaling deep learning is challenging, and there is a
high computational cost (e.g. time, memory and energy)
associated with training neural networks and using them to
make predictions. This is one of the reasons why neural networks have only recently found widespread use [495].
Many have sought to curb these costs, with methods ranging from the very applied (e.g. reduced numerical precision
[496–499]) to the exotic and theoretic (e.g. training small networks to mimic large networks and ensembles [448,500]).
The largest gains in efficiency have come from computation
with GPUs [495,501–505], which excel at the matrix and
vector operations so central to deep learning. The massively
parallel nature of GPUs allows additional optimizations, such
as accelerated mini-batch gradient descent [502,503,506,507].
However, GPUs also have limited memory, making networks
of useful size and complexity difficult to implement on a single
GPU or machine [68,501]. This restriction has sometimes forced
computational biologists to use workarounds or limit the size
of an analysis. Chen et al. [183] inferred the expression level
of all genes with a single neural network, but due to memory
restrictions, they randomly partitioned genes into two separately analysed halves. In other cases, researchers limited the
size of their neural network [29] or the total number of training
instances [401]. Some have also chosen to use standard central
processing unit (CPU) implementations rather than sacrifice
network size or performance [508].
While steady improvements in GPU hardware may alleviate
this issue, it is unclear whether advances will occur quickly
enough to keep pace with the growing biological datasets and
increasingly complex neural networks. Much has been done to
minimize the memory requirements of neural networks [448,
496–499,509,510], but there is also growing interest in specialized
hardware, such as field-programmable gate arrays (FPGAs)
[505,511] and application-specific integrated circuits (ASICs)
[512]. Less software is available for such highly specialized hardware [511]. But specialized hardware promises improvements in
deep learning at reduced time, energy and memory [505]. Specialized hardware may be a difficult investment for those not solely
interested in deep learning, but for those with a deep learning
focus these solutions may become popular.
Distributed computing is a general solution to intense
computational requirements and has enabled many largescale deep learning efforts. Some types of distributed computation [513,514] are not suitable for deep learning [515], but
much progress has been made. There now exist a number
of algorithms [498,515], tools [516–518] and high-level
libraries [519,520] for deep learning in a distributed environment, and it is possible to train very complex networks with
limited infrastructure [521]. Besides handling very large networks, distributed or parallelized approaches offer
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component analysis, per class histograms or a Word2vec
[105] generalization) can be learned directly from input data
or take advantage of other datasets or domain knowledge.
Additionally, in this task, the features are the examples, an
important advantage when it is typical to have 500 000 or
more SNPs and only a few thousand patients. Finally, this
embedding is of a much lower dimension, allowing for a
large reduction in the number of free parameters. In the
example given, the number of free parameters was reduced
from 30 million to 50 000, a factor of 600.
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many datasets. However, such techniques are rarely placed
front and centre in any description of methods and may be
easily overlooked.
For some types of data, especially images, it is straightforward to augment training datasets by splitting a single
labelled example into multiple examples. For example, an
image can easily be rotated, flipped or translated and retain
its label [43]. 3D MRI and 4D fMRI (with time as a dimension) data can be decomposed into sets of 2D images [491].
This can greatly expand the number of training examples
but artificially treats such derived images as independent
instances and sacrifices the structure inherent in the data.
CellCnn trains a model to recognize rare cell populations in
single-cell data by creating training instances that consist of
subsets of cells that are randomly sampled with replacement
from the full dataset [300].
Simulated or semi-synthetic training data have been
employed in multiple biomedical domains, though many of
these ideas are not specific to deep learning. Training and
evaluating on simulated data, for instance, generating synthetic TF binding sites with PWMs [209] or RNA-seq reads
for predicting mRNA transcript boundaries [492], is a standard practice in bioinformatics. This strategy can help
benchmark algorithms when the available gold standard
dataset is imperfect, but it should be paired with an evaluation on real data, as in the prior examples [209,492]. In
rare cases, models trained on simulated data have been
successfully applied directly to real data [492].
Data can be simulated to create negative examples when
only positive training instances are available. DANN [35]
adopts this approach to predict the pathogenicity of genetic
variants using semi-synthetic training data from Combined
Annotation-Dependent Depletion (CADD) [493]. Though
our emphasis here is on the training strategy, it should be
noted that logistic regression outperformed DANN when distinguishing known pathogenic mutations from likely benign
variants in real data. Similarly, a somatic mutation caller
has been trained by injecting mutations into real sequencing
datasets [345]. This method detected mutations in other
semi-synthetic datasets but was not validated on real data.
In settings where the experimental observations are biased
towards positive instances, such as MHC protein and peptide
ligand binding affinity [273], or the negative instances vastly
outnumber the positives, such as high-throughput chemical
screening [398], training datasets have been augmented by
adding additional instances and assuming they are negative.
There is some evidence that this can improve performance
[398], but in other cases, it was only beneficial when the real
training datasets were extremely small [273]. Overall, training
with simulated and semi-simulated data is a valuable idea
for overcoming limited sample sizes but one that requires
more rigorous evaluation of real ground-truth datasets before
we can recommend it for widespread use. There is a risk that
a model will easily discriminate synthetic examples but not
generalize to real data.
Multimodal, multi-task and transfer learning, discussed in
detail below, can also combat data limitations to some degree.
There are also emerging network architectures, such as Diet
Networks for high-dimensional SNP data [494]. These use
multiple networks to drastically reduce the number of free parameters by first flipping the problem and training a network to
predict parameters (weights) for each input (SNP) to learn a
feature embedding. This embedding (e.g. from the principal
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A robust culture of data, code and model sharing would
speed advances in this domain. The cultural barriers to
data sharing, in particular, are perhaps best captured by the
use of the term ‘research parasite’ to describe scientists who
use data from other researchers [530]. A field that honours
only discoveries and not the hard work of generating useful
data will have difficulty encouraging scientists to share
their hard-won data. It is precisely those data that would
help to power deep learning in the domain. Efforts are underway to recognize those who promote an ecosystem of
rigorous sharing and analysis [531].
The sharing of high-quality, labelled datasets will be
especially valuable. In addition, researchers who invest time
to preprocess datasets to be suitable for deep learning can
make the preprocessing code (e.g. Basset [229] and variation
analysis [343]) and cleaned data (e.g. MoleculeNet [410]) publicly available to catalyse further research. However, there are
complex privacy and legal issues involved in sharing patient
data that cannot be ignored. Solving these issues will require
increased understanding of privacy risks and standards specifying acceptable levels. In some domains, high-quality training
data have been generated privately, i.e. high-throughput
chemical screening data at pharmaceutical companies. One
perspective is that there is little expectation or incentive for
this private data to be shared. However, data are not inherently
valuable. Instead, the insights that we glean from them are
where the value lies. Private companies may establish a competitive advantage by releasing data sufficient for improved
methods to be developed. Recently, Ramsundar et al. [532]
did this with an open source platform DeepChem, where
they released four privately generated datasets.
Code sharing and open source licensing are essential for
continued progress in this domain. We strongly advocate
following established best practices for sharing source code,
archiving code in repositories that generate digital object identifiers, and open licensing [533] regardless of the minimal
requirements, or lack thereof, set by journals, conferences or
preprint servers. In addition, it is important for authors to
share not only code for their core models but also scripts
and code used for data cleaning (see above) and hyperparameter optimization. These improve reproducibility and
serve as documentation of the detailed decisions that impact
model performance but may not be exhaustively captured in
a manuscript’s methods text.
Because many deep learning models are often built using
one of several popular software frameworks, it is also possible
to directly share trained predictive models. The availability of

5.7. Multimodal, multi-task and transfer learning
The fact that biomedical datasets often contain a limited
number of instances or labels can cause poor performance of
deep learning algorithms. These models are particularly
prone to overfitting due to their high representational
power. However, transfer learning techniques, also known as
domain adaptation, enable transfer of extracted patterns
between different datasets and even domains. This approach
consists of training a model for the base task and subsequently
reusing the trained model for the target problem. The first step
allows a model to take advantage of a larger amount of data
and/or labels to extract better feature representations. Transferring learned features in deep neural networks improves
performance compared to randomly initialized features even
when pre-training and target sets are dissimilar. However,
transferability of features decreases as the distance between
the base task and target task increases [535].
In image analysis, previous examples of deep transfer
learning applications proved large-scale natural image sets
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5.6. Data, code and model sharing

pre-trained models can accelerate research, with image classifiers as an apt example. A pre-trained neural network can be
quickly fine-tuned on new data and used in transfer learning,
as discussed below. Taking this idea to the extreme, genomic
data have been artificially encoded as images in order to
benefit from pre-trained image classifiers [341]. ‘Model
zoos’—collections of pre-trained models—are not yet
common in biomedical domains but have started to appear
in genomics applications [296,534]. However, it is important
to note that sharing models trained on individual data requires
great care, because deep learning models can be attacked to
identify examples used in training. One possible solution
to protect individual samples includes training models under
differential privacy [155], which has been used in the biomedical domain [158]. We discussed this issue as well as
recent techniques to mitigate these concerns in the patient
categorization section.
DeepChem [406,410,412] and DragoNN (Deep RegulAtory
GenOmic Neural Networks) [534] exemplify the benefits of
sharing pre-trained models and code under an open source
licence. DeepChem, which targets drug discovery and quantum chemistry, has actively encouraged and received
community contributions of learning algorithms and benchmarking datasets. As a consequence, it now supports a large
suite of machine learning approaches, both deep learning
and competing strategies, that can be run on diverse test
cases. This realistic, continual evaluation will play a critical
role in assessing which techniques are most promising for
chemical screening and drug discovery. Like formal, organized
challenges such as the ENCODE-DREAM in vivo TF Binding
Site Prediction Challenge [215], DeepChem provides a forum
for the fair, critical evaluations that are not always conducted
in individual methodological papers, which can be biased
towards favouring a new proposed algorithm. Likewise
DragoNN offers not only code and a model zoo but also a
detailed tutorial and partner package for simulating training
data. These resources, especially the ability to simulate datasets
that are sufficiently complex to demonstrate the challenges of
training neural networks but small enough to train quickly
on a CPU, are important for training students and attracting
machine learning researchers to problems in genomics and
healthcare.
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other advantages, such as improved ensembling [522] or
accelerated hyperparameter optimization [523,524].
Cloud computing, which has already seen wide adoption in
genomics [525], could facilitate easier sharing of the large datasets common to biology [526,527], and may be key to scaling
deep learning. Cloud computing affords researchers flexibility,
and enables the use of specialized hardware (e.g. FPGAs, ASICs
and GPUs) without major investment. As such, it could be
easier to address the different challenges associated with
the multitudinous layers and architectures available [528].
Though many are reluctant to store sensitive data (e.g. patient
EHRs) in the cloud, secure, regulation-compliant cloud services
do exist [529].
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of hepatocellular carcinoma patients. This multimodal
approach that treated different omic data types as different
modalities outperformed both traditional methods (principal
component analysis) and single-omic models. Interestingly,
multi-omic model performance did not improve when combined with clinical information, suggesting that the model
was able to capture redundant contributions of clinical features
through their correlated genomic features. Chen et al. [178]
used DBNs to learn phosphorylation states of a common set
of signalling proteins in primary cultured bronchial cells collected from rats and humans treated with distinct stimuli. By
interpreting species as different modalities representing similar
high-level concepts, they showed that DBNs were able to capture cross-species representation of signalling mechanisms in
response to a common stimuli. Another application used
DBNs for joint unsupervised feature learning from cancer datasets containing gene expression, DNA methylation and
miRNA expression data [186]. This approach allowed for the
capture of intrinsic relationships in different modalities and
for better clustering performance over conventional k-means.
Multimodal learning with CNNs is usually implemented
as a collection of individual networks in which each learns
representations from the single data type. These individual representations are further concatenated before or within fully
connected layers. FIDDLE [542] is an example of a multimodal
CNN that represents an ensemble of individual networks that
take NET-seq, MNase-seq, ChIP-seq, RNA-seq and raw DNA
sequence as input to predict transcription start sites. The combined model radically improves performance over separately
trained datatype-specific networks, suggesting that it learns
the synergistic relationship between datasets.
Multi-task learning is an approach related to transfer
learning. In a multi-task learning framework, a model
learns a number of tasks simultaneously such that features
are shared across them. DeepSEA [211] implemented multitask joint learning of diverse chromatin factors from raw
DNA sequence. This allowed a sequence feature that was
effective in recognizing binding of a specific TF to be simultaneously used by another predictor for a physically
interacting TF. Similarly, TFImpute [193] learned information
shared across TFs and cell lines to predict cell-specific TF
binding for TF-cell line combinations. Yoon et al. [104]
demonstrated that predicting the primary cancer site from
cancer pathology reports together with its laterality substantially improved the performance for the latter task, indicating
that multi-task learning can effectively leverage the commonality between two tasks using a shared representation.
Many studies employed multi-task learning to predict chemical bioactivity [390,394] and drug toxicity [395,543]. Kearnes
et al. [388] systematically compared single-task and multi-task
models for ADMET properties and found that multi-task
learning generally improved performance. Smaller datasets
tended to benefit more than larger datasets.
Multi-task learning is complementary to multimodal and
transfer learning. All three techniques can be used together in
the same model. For example, Zhang et al. [536] combined
deep model-based transfer and multi-task learning for
cross-domain image annotation. One could imagine extending that approach also to multimodal inputs. A common
characteristic of these methods is a better generalization of
extracted features at various hierarchical levels of abstraction,
which is attained by leveraging relationships between
various inputs and task objectives.
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[46] to be useful for pre-training models that serve as generic
feature extractors for various types of biological images
[15,286,536,537]. More recently, deep learning models predicted protein subcellular localization for proteins not
originally present in a training set [538]. Moreover, learned
features performed reasonably well even when applied to
images obtained using different fluorescent labels, imaging
techniques and different cell types [539]. However, there are
no established theoretical guarantees for feature transferability between distant domains such as natural images and
various modalities of biological imaging. Because learned
patterns are represented in deep neural networks in a layerwise hierarchical fashion, this issue is usually addressed by
fixing an empirically chosen number of layers that preserve
generic characteristics of both training and target datasets.
The model is then fine-tuned by re-training top layers on
the specific dataset in order to re-learn domain-specific
high-level concepts (e.g. fine-tuning for radiology image
classification [58]). Fine-tuning of specific biological datasets
enables more focused predictions.
In genomics, the Basset package [229] for predicting chromatin accessibility was shown to rapidly learn and accurately
predict on new data by leveraging a model pre-trained on
available public data. To simulate this scenario, authors put
aside 15 of 164 cell-type datasets and trained the Basset
model on the remaining 149 datasets. Then, they fine-tuned
the model with one training pass of each of the remaining datasets and achieved results close to the model trained on all
164 datasets together. In another example, Min et al. [230]
demonstrated how training on the experimentally validated
FANTOM5 permissive enhancer dataset followed by finetuning on ENCODE enhancer datasets improved cell-typespecific predictions, outperforming state-of-the-art results. In
drug design, general RNN models trained to generate molecules from the ChEMBL database have been fine-tuned to
produce drug-like compounds for specific targets [423,426].
Related to transfer learning, multimodal learning
assumes simultaneous learning from various types of
inputs, such as images and text. It can capture features that
describe common concepts across input modalities. Generative graphical models like RBMs, deep Boltzmann machines
and DBNs, demonstrate successful extraction of more informative features for one modality (images or video) when
jointly learned with other modalities (audio or text) [540].
Deep graphical models such as DBNs are well suited for multimodal learning tasks because they learn a joint probability
distribution from inputs. They can be pre-trained in an unsupervised fashion on large unlabelled data and then finetuned on a smaller number of labelled examples. When
labels are available, CNNs are ubiquitously used because
they can be trained end-to-end with backpropagation and
demonstrate state-of-the-art performance in many discriminative tasks [15].
Jha et al. [192] showed that integrated training delivered
better performance than individual networks. They compared
a number of feed-forward architectures trained on RNA-seq
data with and without an additional set of CLIP-seq, knockdown and over-expression based input features. The
integrative deep model generalized well for combined data,
offering a large performance improvement for alternative splicing event estimation. Chaudhary et al. [541] trained a deep
autoencoder model jointly on RNA-seq, miRNA-seq and
methylation data from TCGA to predict survival subgroups
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Deep learning-based methods now match or surpass the previous state of the art in a diverse array of tasks in patient and
disease categorization, fundamental biological study, genomics and treatment development. Returning to our central
question: given this rapid progress, has deep learning transformed the study of human disease? Though the answer is
highly dependent on the specific domain and problem being
addressed, we conclude that deep learning has not yet realized
its transformative potential or induced a strategic inflection
point. Despite its dominance over competing machine learning
approaches in many of the areas reviewed here and quantitative improvements in predictive performance, deep learning
has not yet definitively ‘solved’ these problems.
As an analogy, consider recent progress in conversational
speech recognition. Since 2009, there have been drastic performance improvements with error rates dropping from
more than 20% to less than 6% [545] and finally approaching
or exceeding human performance in the past year [546,547].
The phenomenal improvements on benchmark datasets are
undeniable, but greatly reducing the error rate on these
benchmarks did not fundamentally transform the domain.
Widespread adoption of conversational speech technologies
will require solving the problem, i.e. methods that surpass
human performance, and persuading users to adopt them
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6. Conclusion

[545]. We see parallels in healthcare, where achieving the
full potential of deep learning will require outstanding predictive performance as well as acceptance and adoption by
biologists and clinicians. These experts will rightfully
demand rigorous evidence that deep learning has impacted
their respective disciplines—elucidated new biological mechanisms and improved patient outcomes—to be convinced
that the promises of deep learning are more substantive
than those of previous generations of artificial intelligence.
Some of the areas we have discussed are closer to surpassing this lofty bar than others, generally, those that are more
similar to the non-biomedical tasks that are now monopolized
by deep learning. In medical imaging, diabetic retinopathy
[50], diabetic macular oedema [50], tuberculosis [59] and skin
lesion [5] classifiers are highly accurate and comparable to
clinician performance.
In other domains, perfect accuracy will not be required
because deep learning will primarily prioritize experiments
and assist discovery. For example, in chemical screening for
drug discovery, a deep learning system that successfully
identifies dozens or hundreds of target-specific, active small
molecules from a massive search space would have immense
practical value even if its overall precision is modest. In medical imaging, deep learning can point an expert to the most
challenging cases that require manual review [59], though
the risk of false negatives must be addressed. In protein structure prediction, errors in individual residue–residue contacts
can be tolerated when using the contacts jointly for 3D structure modelling. Improved contact map predictions [29] have
led to notable improvements in fold and 3D structure prediction for some of the most challenging proteins, such as
membrane proteins [252].
Conversely, the most challenging tasks may be those in
which predictions are used directly for downstream modelling or decision-making, especially in the clinic. As an
example, errors in sequence variant calling will be amplified
if they are used directly for genome-wide association studies.
In addition, the stochasticity and complexity of biological systems imply that for some problems, for instance, predicting
gene regulation in disease, perfect accuracy will be unattainable.
We are witnessing deep learning models achieving humanlevel performance across a number of biomedical domains.
However, machine learning algorithms, including deep
neural networks, are also prone to mistakes that humans are
much less likely to make, such as misclassification of adversarial examples [548,549], a reminder that these algorithms do not
understand the semantics of the objects presented. It may be
impossible to guarantee that a model is not susceptible to
adversarial examples, but work in this area is continuing
[550,551]. Cooperation between human experts and deep learning algorithms addresses many of these challenges and can
achieve better performance than either individually [65]. For
sample and patient classification tasks, we expect deep learning
methods to augment clinicians and biomedical researchers.
We are optimistic about the future of deep learning in
biology and medicine. It is by no means inevitable that deep
learning will revolutionize these domains, but given how
rapidly the field is evolving, we are confident that its full potential in biomedicine has not been explored. We have highlighted
numerous challenges beyond improving training and predictive accuracies, such as preserving patient privacy and
interpreting models. Ongoing research has begun to address
these problems and shown that they are not insurmountable.
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Despite demonstrated improvements, transfer learning
approaches pose challenges. There are no theoretically sound
principles for pre-training and fine-tuning. Best practice recommendations are heuristic and must account for additional
hyper-parameters that depend on specific deep architectures,
sizes of the pre-training and target datasets, and similarity of
domains. However, the similarity of datasets and domains in
transfer learning and relatedness of tasks in multi-task learning
are difficult to access. Most studies address these limitations by
empirical evaluation of the model. Unfortunately, negative
results are typically not reported. A deep CNN trained on natural images boosts performance in radiographic images [58].
However, due to differences in imaging domains, the target
task required either re-training the initial model from scratch
with special preprocessing or fine-tuning of the whole network
on radiographs with heavy data augmentation to avoid overfitting. Exclusively fine-tuning top layers led to much lower
validation accuracy (81.4 versus 99.5). Fine-tuning the aforementioned Basset model with more than one pass resulted in
overfitting [229]. DeepChem successfully improved results
for low-data drug discovery with one-shot learning for related
tasks. However, it clearly demonstrated the limitations of
cross-task generalization across unrelated tasks in one-shot
models, specifically nuclear receptor assays and patient
adverse reactions [406].
In the medical domain, multimodal, multi-task and transfer
learning strategies not only inherit most methodological issues
from natural image, text and audio domains, but also pose
domain-specific challenges. There is a compelling need for the
development of privacy-preserving transfer learning algorithms, such as Private Aggregation of Teacher Ensembles
[544]. We suggest that these types of models deserve deeper
investigation to establish sound theoretical guarantees and
determine limits for the transferability of features between
various closely related and distant learning tasks.
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7.1. Continuous collaborative manuscript drafting
We recognized that deep learning in precision medicine is a
rapidly developing area. Hence, diverse expertise was required
to provide a forward-looking perspective. Accordingly, we collaboratively wrote this review in the open, enabling anyone with
expertise to contribute. We wrote the manuscript in markdown
and tracked changes using git. Contributions were handled
through GitHub, with individuals submitting ‘pull requests’ to
suggest additions to the manuscript.
To facilitate citation, we defined a markdown citation syntax.
We supported citations to the following identifier types (in order
of preference): DOIs, PubMed Central IDs, PubMed IDs, arXiv
IDs and URLs. References were automatically generated from
citation metadata by querying APIs to generate Citation Style
Language JSON items for each reference. Pandoc and pandocciteproc converted the markdown to HTML and PDF, while rendering the formatted citations and references. In total, referenced
works consisted of 372 DOIs, six PubMed Central records, 129
arXiv manuscripts and 48 URLs (webpages as well as manuscripts lacking standardized identifiers).
We implemented continuous analysis so the manuscript was
automatically regenerated whenever the source changed [150].
We configured Travis CI—a continuous integration service—to
fetch new citation metadata and rebuild the manuscript for
every commit. Accordingly, formatting or citation errors in pull
requests would cause the Travis CI build to fail, automating
quality control. In addition, the build process renders templated
variables, such as the reference counts mentioned above, to automate the updating of dynamic content. When contributions were
merged into the master branch, Travis CI deployed the built
manuscript by committing back to the GitHub repository. As a
result, the latest manuscript version is always available at
https://greenelab.github.io/deep-review. To ensure a consistent
software environment, we defined a versioned conda environment of the software dependencies.

Data accessibility. This article has no additional data.
Authors’ contributions. We created an open repository on the GitHub version control platform (greenelab/deep-review) [555]. Here, we
engaged with numerous authors from papers within and outside of
the area. The manuscript was drafted via GitHub commits by 36 individuals who met the ICMJE standards of authorship. These were
individuals who contributed to the review of the literature; drafted
the manuscript or provided substantial critical revisions; approved
the final manuscript draft; and agreed to be accountable in all aspects
of the work. Individuals who did not contribute in all of these ways,
but who did participate, are acknowledged below. We grouped
authors into the following four classes of approximately equal contributions and randomly ordered authors within each contribution
class. Drafted multiple sub-sections along with extensive editing,
pull request reviews or discussion: A.A.K., B.K.B., B.T.D., D.S.H.,
E.F., G.P.W., M.M.H., M.Z., P.A. and T.C. Drafted one or more subsections: A.E.C., A.M.A., A.S., B.J.L., C.A.L., E.M.C., G.L.R., J.I.,
J.L., J.X., S.C.T., S.W., W.X. and Z.L. Revised specific sub-sections
or supervised drafting one or more sub-sections: A.H., A.K., D.D.,
D.J.H., L.K.W., M.H.S.S., S.J.S., S.M.B., Y.P. and Y.Q. Drafted subsections, edited the manuscript, reviewed pull requests and coordinated
co-authors: A.G. and C.S.G.

Competing interests. A.K. is on the Advisory Board of Deep Genomics
Inc. E.F. is a full-time employee of GlaxoSmithKline. The remaining
authors have no competing interests to declare.

Funding. We acknowledge funding from the Gordon and Betty Moore
Foundation awards GBMF4552 (C.S.G. and D.S.H.) and GBMF4563
(D.J.H.); the Howard Hughes Medical Institute (S.C.T.); the National
Institutes of Health awards DP2GM123485 (A.K.), P30CA051008
(S.M.B.),
R01AI116794
(B.K.B.),
R01GM089652
(A.E.C.),
R01GM089753 (J.X.), R01LM012222 (S.J.S.), R01LM012482 (S.J.S.),
R21CA220398 (S.M.B.), T32GM007753 (B.T.D.), T32HG000046
(G.P.W.) and U54AI117924 (A.G.); the National Institutes of Health
Intramural Research Program and National Library of Medicine
(Y.P. and Z.L.); the National Science Foundation awards 1245632
(G.L.R.), 1531594 (E.M.C.) and 1564955 (J.X.); the Natural Sciences
and Engineering Research Council of Canada award RGPIN-20153948 (M.M.H.) and the Roy and Diana Vagelos Scholars Program
in the Molecular Life Sciences (M.Z.).
Acknowledgements. We gratefully acknowledge Christof Angermueller,
Kumardeep Chaudhary, Gökcen Eraslan, Mikael Huss, Bharath Ramsundar and Xun Zhu for their discussion of the manuscript and
reviewed papers on GitHub. We thank Aaron Sheldon, who contributed text but did not formally approve the manuscript; Anna Greene
for a careful proofreading of the manuscript in advance of the first
submission; Sebastian Raschka for clarifying edits to the abstract
and introduction and Robert Gieseke, Ruibang Luo, Stephen Ra,
Sourav Singh and GitHub user snikumbh for correcting typos,
formatting and references.

References
1.

2.
3.

Stephens ZD et al. 2015 Big data: astronomical or
genomical? PLoS Biol. 13, e1002195. (doi:10.1371/
journal.pbio.1002195)
LeCun Y, Bengio Y, Hinton G. 2015 Deep learning.
Nature 521, 436 –444. (doi:10.1038/nature14539)
Baldi P, Sadowski P, Whiteson D. 2014 Searching for
exotic particles in high-energy physics with deep

4.

5.

learning. Nat. Comm. 5, 1. (doi:10.1038/
ncomms5308)
Goh GB, Hodas NO, Vishnu A. 2017 Deep learning
for computational chemistry. J. Comput. Chem. 38,
1291 –1307. (doi:10.1002/jcc.24764)
Esteva A, Kuprel B, Novoa RA, Ko J, Swetter SM,
Blau HM, Thrun S. 2017 Dermatologist-level

6.

classification of skin cancer with deep neural
networks. Nature 542, 115– 118. (doi:10.1038/
nature21056)
Wu Y et al. 2016 Google’s neural machine
translation system: bridging the gap between
human and machine translation. arXiv. (https://
arxiv.org/abs/1609.08144v2)

34

J. R. Soc. Interface 15: 20170387

7. Methods

In addition, we instructed the Travis CI deployment script to
perform blockchain timestamping [552,553]. Using OpenTimestamps, we submitted hashes for the manuscript and the source
git commit for timestamping in the Bitcoin blockchain [554].
These timestamps attest that a given version of this manuscript
(and its history) existed at a given point in time. The ability to
irrefutably prove manuscript existence at a past time could be
important to establish scientific precedence and enforce an
immutable record of authorship.

rsif.royalsocietypublishing.org

Deep learning offers the flexibility to model data in its most
natural form, for example, longer DNA sequences instead of
k-mers for TF binding prediction and molecular graphs instead
of pre-computed bit vectors for drug discovery. These flexible
input feature representations have spurred creative modelling
approaches that would be infeasible with other machine
learning techniques. Unsupervised methods are currently
less developed than their supervised counterparts, but they
may have the most potential because of how expensive and
time-consuming it is to label large amounts of biomedical
data. If future deep learning algorithms can summarize very
large collections of input data into interpretable models that
spur scientists to ask questions that they did not know how
to ask, it will be clear that deep learning has transformed
biology and medicine.

7.

9.

Downloaded from https://royalsocietypublishing.org/ on 06 September 2022

11.
12.

13.

14.

15.

16.

17.

18.

19.

20.

21.

22.

23.

24.

26.

27.

28.

29.

30.

31.

32.

33.

34.

35.

36.

37.

38. Wang Y, Zeng J. 2013 Predicting drug-target
interactions using restricted Boltzmann machines.
Bioinformatics 29, i126 –i134. (doi:10.1093/
bioinformatics/btt234)
39. Wen M, Zhang Z, Niu S, Sha H, Yang R, Yun Y, Lu H.
2017 Deep-learning-based drug –target interaction
prediction. J. Proteome Res. 16, 1401–1409.
(doi:10.1021/acs.jproteome.6b00618)
40. Shen D, Wu G, Suk H. 2017 Deep learning in
medical image analysis. Annu. Rev. Biomed. Eng.
19, 221 –248. (doi:10.1146/annurev-bioeng071516-044442)
41. Dhungel N, Carneiro G, Bradley AP. 2015 Deep
learning and structured prediction for the
segmentation of mass in mammograms. In 18th
International Conference on Medical Image
Computing and Computer Assisted Intervention
(MICCAI), Munich, Germany, October. Lecture Notes
in Computer Science, vol. 9349. Cham, Switzerland:
Springer.
42. Dhungel N, Carneiro G, Bradley AP. 2016 The
automated learning of deep features for breast
mass classification from mammograms. In Medical
image computing and computer-assisted
intervention – MICCAI 2016. Lecture Notes in
Computer Science, vol. 9901. Cham: Springer.
43. Zhu W, Lou Q, Scott Vang Y, Xie X. 2016 Deep
multi-instance networks with sparse label
assignment for whole mammogram classification.
bioRxiv. (doi:10.1101/095794)
44. Zhu W, Xie X. 2016 Adversarial deep structural
networks for mammographic mass segmentation.
bioRxiv (doi:10.1101/095786)
45. Dhungel N, Carneiro G, Bradley AP. 2017 A deep
learning approach for the analysis of masses in
mammograms with minimal user intervention.
Med. Image Anal. 37, 114 –128. (doi:10.1016/j.
media.2017.01.009)
46. Russakovsky O et al. 2015 ImageNet large scale
visual recognition challenge. Int. J. Comput.
Vision 115, 211–252. (doi:10.1007/s11263-0150816-y)
47. Pratt H, Coenen F, Broadbent DM, Harding SP,
Zheng Y. 2016 Convolutional neural networks
for diabetic retinopathy. Procedia Comp. Sci. 90,
200–205. (doi:10.1016/j.procs.2016.07.014)
48. Abràmoff DM, Lou Y, Erginay A, Clarida W, Amelon
R, Folk JC, Niemeijer M. 2016 Improved automated
detection of diabetic retinopathy on a publicly
available dataset through integration of deep
learning. Invest. Opthalmol. Vis. Sci. 57, 5200.
(doi:10.1167/iovs.16-19964)
49. Leibig C, Allken V, Seckin Ayhan M, Berens P, Wahl
S. 2016 Leveraging uncertainty information from
deep neural networks for disease detection. bioRxiv.
(doi:10.1101/084210)
50. Gulshan V et al. 2016 Development and validation
of a deep learning algorithm for detection of
diabetic retinopathy in retinal fundus photographs.
JAMA 316, 2402. (doi:10.1001/jama.2016.17216)
51. Codella N, Nguyen Q-B, Pankanti S, Gutman D,
Helba B, Halpern A, Smith JR. 2016 Deep learning
ensembles for melanoma recognition in dermoscopy

35

J. R. Soc. Interface 15: 20170387

10.

25.

J. Clin. Oncol. 27, 1160–1167. (doi:10.1200/jco.
2008.18.1370)
Mayer IA, Abramson VG, Lehmann BD, Pietenpol JA.
2014 New strategies for triple-negative breast
cancer—deciphering the heterogeneity. Clin.
Cancer Res. 20, 782– 790. (doi:10.1158/1078-0432.
ccr-13-0583)
Tan J, Ung M, Cheng C, Greene CS. 2014
Unsupervised feature construction and knowledge
extraction from genome-wide assays of breast
cancer with denoising autoencoders. Pac Symp
Biocomput. 20, 132–143. (doi:10.1142/
9789814644730_0014)
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Esteban C, Hyland SL, Rätsch G. 2017 Real-valued
(medical) time series generation with recurrent

rsif.royalsocietypublishing.org

128. Implementations by Phenotype j PheKB. 2017
(https://phekb.org/implementations)
129. Halpern Y, Horng S, Choi Y, Sontag D. 2016
Electronic medical record phenotyping using the
anchor and learn framework. J. Am. Med. Inform.
Assoc. 23, 731 –740. (doi:10.1093/jamia/ocw011)
130. Ratner A, De Sa C, Wu S, Selsam D, Ré C. 2016 Data
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